

Conference Program



American Association for the Treatment of Opioid Dependence, Inc.

NATIONAL CONFERENCE

**Treatment & Recovery:**  
*People & Outcomes*

new york city  
2009

**APRIL 25 - 29, 2009**  
**HILTON NEW YORK**

Joint Sponsors: American Association for the Treatment of Opioid Dependence, Inc. & American Society of Addiction Medicine

[www.aatod.org](http://www.aatod.org)

## CONFERENCE PLANNING COMMITTEE

**Ira J. Marion, MA**  
Conference Chair

**Mark W. Parrino, MPA**  
President  
*American Association for the Treatment of Opioid Dependence, Inc.*

**Carleen Maxwell, MPH**  
Project Director  
*American Association for the Treatment of Opioid Dependence, Inc.*

**Angelina Budija**  
Administrative Coordinator  
*American Association for the Treatment of Opioid Dependence, Inc.*

**Alexandra Springer**  
Meeting Manager  
*Talley Management Group, Inc.*

**Wendy Stevens**  
Tradeshaw Manager  
*Talley Management Group, Inc.*

## Board of Directors

<b>Mark W. Parrino, MPA</b> President	NY
<b>Ira J. Marion, MA</b> First Vice-President	NY
<b>George Stavros, MD</b> Second Vice President	AZ
<b>Michael Rizzi</b> Treasurer	RI
<b>Jina K. Thalmann, LCSW</b> Secretary	FL

## Board Members

<b>Richard Bilangi, MS</b>	CT
<b>Roye T. Brown, MS</b>	LA
<b>Carol Butler, MA</b>	MD
<b>Brian Crissman, BA</b>	DC
<b>Eric Ennis, LCSW</b>	CO
<b>Steve Flora</b>	AL
<b>Richard Froncillo, LCDS</b>	PA
<b>Gregory Hardin, CADACII</b>	IN
<b>Edward J. Higgins, MA</b>	NJ
<b>Ron Jackson, MSW</b>	WA
<b>Edward G. Johnson, LPC</b>	SC
<b>Janice F. Kauffman, RN</b>	MA
<b>Jason Kletter, PhD</b>	CA
<b>Shirley Linzy, RN</b>	NV
<b>Kate Mahoney, LCSW</b>	IL
<b>Brian McCarroll, DO</b>	MI
<b>Paul McLaughlin, MA</b>	CT
<b>Joel Millard, DSW</b>	UT
<b>Edward V. Ohlinger</b>	VA
<b>Stacey Pearce</b>	GA
<b>Carrie Perkins</b>	ME
<b>Galen E. Rogers, PhD</b>	MEXICO
<b>Keith E. Spare, MS, MDiv, LPC</b>	MO

## 2009 CONFERENCE COMMITTEES

### Awards Committee

**Jason Kletter, PhD - Committee Chair**

**Stacey Pearce**

**Michael Rizzi**

**George Stavros, MD**

**Jina K. Thalmann, LCSW**

### Hospitality Committee

**Haynes - Committee Chair**

**Dale Wallace-Thompson, MS**

**Caroline Waterman, MA**

### International Committee

**Michael Rizzi - Committee Chair**

**Icro Maremmanni, MD**

**Ira J. Marion, MA**

**Mark W. Parrino, MPA**

### Plenary Committee

**Herbert Barish, MSW - Committee Chair**

**Ira J. Marion, MA**

**Robert B. Millman, MD**

**Mark W. Parrino, MPA**

### Public Relations Committee

**Daniel McGill - Committee Chair**

**Dianne Henk**

**Jim Mandler**

**Nancy Moon**

**Loretta Parsons-Poole**

### Volunteer Committee

**Kathryn Williams, LMSW - Committee Chair**

**Felice Bradford Richards, BA**

**Celia Harewood, MA**

**Marie Marciano, LMSW**

**Glorice Sanders, RN**

**Martin Ringer**

### Workshop Committee

**Ron Jackson, MSW - Committee Chair**

**Candace Baker, MSW**

**Jennifer Fan, PharmD**

**Belinda Greenfield, MA**

**Petra Jacobs, MD**

**Patti Juliana, ACSW**

**Karol Kaltenbach, PhD**

**Chris Kelly**

**Judith Martin, MD**

**Dana Moulton, CMA**

**Susan Storti, RN**

**Michael Rizzi**

**Joan Zweben, PhD**



Dear Colleagues, Patients, Advocates, Stakeholders and Friends:

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), and our hosts, the New York State Office of Alcoholism and Substance Abuse Services (OASAS) and COMPA – New York State's Opioid Treatment Coalition, it is my great pleasure to welcome you to New York City, to the Hilton Hotel and to our 2009 AATOD Conference. Our planning committee and AATOD staff has worked hard to make AATOD's 25th Anniversary Conference a truly memorable event. We gather together in very challenging times, with a new administration in Washington and a renewed hope for change for our field and certainly for those who rely on the care we provide. Our conference theme, "Treatment and Recovery: People and Outcomes" challenges us to think of those still in need of treatment, as well as our patients and is addressed in our conference program. As you review the Plenary, Workshop and Hot Topics as well as the pre-conference training opportunities, you will appreciate the efforts of our planners to provide you with a premier training and policy event focusing on opioid dependence and medication assisted treatment. Our conference respects the diversity in our field, and the difficult challenge in restoring lives, families and communities. It is my hope that as you plan your conference schedule, you make sure to allow time to see our beautiful city as spring is in bloom – Central Park, museums, Times Square, restaurant row – all just outside the Hilton's front door.

AATOD and our planning Committee are well aware of the challenges we face as patients, staff, advocates, stakeholders and policy makers. As we convene in New York, critical issues confront OTPs, here and across the globe. We have thoughtfully tried to focus on our beginnings, the passion and concern we all have to provide recovery opportunities for our patients, while eliminating the stigma that pervades our treatment modality. Now, we face new challenges, transforming our programs to provide quality, individualized services with respect and dignity, incorporating evidence based practice and measuring what works and for whom. Our plenary sessions have been designed to focus on medication assisted treatment as a vital part of the continuum of care for those dependent on opioids. You will hear about the transformation process now ongoing in New York State, initiated by our OASAS Commissioner, Karen Carpenter-Palumbo. On Tuesday, CSAT Director Dr. H. Westley Clark will provide a guide to the integration of recovery oriented systems of care in OTP, joined by renowned recovery expert, William White and two individuals whose lives were changed by medication assisted treatment. Our closing plenary will look to our future and forge a pathway to fight the stigma that so easily discourages our patients and our staff, addressing ways to generate public support for our work.

I invite you to participate in all our sessions, to spend time in our exhibition hall, talking to the many vendors and exhibitors that support our field and view their offerings. I urge you to speak up at our hot topic roundtables making your voice and ideas heard. Attend the workshops, posters and other conference activities, packed with information and ideas to improve our programs. We've tried to provide activities of interest to everyone – pre-conference trainings, the open AATOD Board meeting Saturday afternoon, our Sunday Opening reception and, the memorable Awards Banquet, where ten people have been chosen to receive the Nyswander/Dole "Marie" award, this year presented by Ms. Anita Townley, secretary, friend and confidante for twenty years to Marie Nyswander and to Vincent Dole, and a medical maintenance patient since that program began. In addition, at this banquet, the AATOD Board will confer our "Friend of the Field" award and the "Richard Lane/Robert Holden Patient Advocacy Award."

I am confident that this conference will be a memorable, moving event from the moment you arrive to the Closing Plenary Session. For those who wish, tours of some of our NYC clinics will also be available just after the Closing session. On behalf of the many people who have worked so hard to construct this exciting conference event, I welcome you to the Big Apple, New York, the "city that never sleeps". I extend my heartfelt thanks to the staff of AATOD, our Committee Chairs and committee members and to Talley Management for helping to make this memorable conference.

Enjoy the conference, the social events and our wondrous New York City. I look forward to meeting many of you.



Ira J. Marion, MA  
2009 Conference Chair



American Association for the Treatment of Opioid Dependence, Inc.

**Treatment & Recovery: People & Outcomes**

## CONFERENCE AT A GLANCE

**ALL EVENTS AND TIMES LISTED  
ARE SUBJECT TO CHANGE!**

DAY	DATE	TIME	EVENT
Saturday	April 25	7:00 AM – 4:00 PM	Registration Open
		8:00 AM – 5:00 PM	The Certified Methadone Advocate (CMA) Training Course
		8:00 AM – 5:30 PM	Buprenorphine and Office-Based Treatment of Opioid Dependence
		8:30 AM – 5:00 PM	Performance Improvement in Opioid Treatment
		3:00 PM – 5:00 PM	The Physician Clinical Support System
		5:00 PM – 8:45 PM	AATOD Open Board Meeting
Sunday	April 26	7:30 AM – 7:30 PM	Registration Open
		8:00 AM – 5:30 PM	Opioid Maintenance Pharmacotherapy: A Course for Clinicians
		8:30 AM – 12:30 PM	Countering Opioid Stigma: Communicating Messages to Influence Public Perception
		9:00 AM – 12:00 PM	Opioid Treatment Program Accreditation Town Hall Meeting
		9:00 AM – 5:30 PM	State Opioid Treatment Authorities' Meeting (Closed Session for State and Federal Officials)
		9:30 AM – 12:00 PM	Opioid Analgesics and Pain in Opioid Dependence Treatment - New Research Findings, Clinical Implications
		1:00 PM – 4:00 PM	Risk Management in the OTP
		1:00 PM – 5:00 PM	Hepatitis Education for Opioid Treatment Providers
		1:00 PM – 5:00 PM	European Opiate Addiction Treatment Association (EUROPAD)
		1:00 PM – 5:00 PM	Trends and Changes in the Quality Framework Called "Accreditation"
		2:00 PM – 5:00 PM	Exhibit Hours
		5:30 PM – 7:30 PM	Welcome Reception
		7:30 PM – 8:30 PM	Methadone Anonymous Meeting (Open)
Monday	April 27	7:30 AM – 7:00 PM	Registration Open
		7:30 AM – 8:30 AM	Continental Breakfast in Exhibit Hall
		7:30 AM – 4:30 PM	Exhibit Hours
		7:30 AM – 4:30 PM	Posters in Exhibit Hall
		8:45 AM – 10:15 AM	Opening Plenary Session - Meeting Challenges in Turbulent Times: New York State's Transformed Treatment System and Continuum of Care
		10:30 AM – 12:00 PM	Workshop Sessions
		12:00 PM – 1:30 PM	Lunch (on your own)
		1:30 PM – 3:00 PM	Workshop Session/Hot Topic Round Tables
		3:00 PM – 4:00 PM	Exhibitors Networking Break in Exhibit Hall
		4:00 PM – 5:30 PM	Workshop Sessions
		6:30 PM – 8:00 PM	Town Hall: A Continuing Community Discussion of How OTPs and the Treatment Community Can Work Together to Prepare for the Next "Service Discontinuity"
		7:00 PM – 8:30 PM	Methadone Anonymous Meeting (Open)
Tuesday	April 28	7:30 AM – 3:00 PM	Registration Open
		7:30 AM – 8:30 AM	Continental Breakfast in Exhibit Hall
		7:30 AM – 8:45 AM	Poster Author Session
		7:30 AM – 1:30 PM	Exhibit Hours
		7:30 AM – 1:30 PM	Posters in Exhibit Hall
		8:45 AM – 10:15 AM	Middle Plenary Session - Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes
		10:30 AM – 12:00 PM	Workshop Sessions
		12:00 PM – 1:30 PM	Lunch (on your own)
		1:30 PM – 3:00 PM	Workshop Sessions
		5:00 PM – 8:00 PM	Registration Open
		7:00 PM – 9:30 PM	Awards Banquet
		9:30 PM – 10:30 PM	Methadone Anonymous Meeting (Open)
Wednesday	April 29	7:00 AM – 1:00 PM	Registration Open
		7:00 AM – 8:00 AM	Continental Breakfast
		8:00 AM – 9:30 AM	Workshop Sessions
		9:45 AM – 11:15 AM	Workshop Sessions
		11:30 AM – 12:45 PM	Closing Plenary Session - Policy, Programs and People
		1:00 PM – 3:30 PM	Clinic Tours

## PRE-CONFERENCE SESSIONS Saturday, April 25, 2009

8:00 AM - 5:00 PM

*Nassau Suite*

### The Certified Methadone Advocate (CMA) Training Course

Walter Ginter, CMA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY

Joycelyn Woods, MA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY

J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL

Nicholas Reuter, MPH, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Rockville, MD

Belinda Greenfield, EdM, CRC, NYS OASAS, Teaneck, NJ

Dana Moulton, MATS, National Alliance of Methadone Advocates (NAMA); MA NAMA, Marlboro, MA

Howard Lotsof, BFA, National Alliance of Methadone Advocates (NAMA); Dora Weiner Foundation, Staten Island, NY

Donna Schoen, CMA; LI NAMA, Long Island, NY

Kerry Wolf, ADN, ARM Texas; We Speak Methadone Forum (NAMA), Cedar, TX

The leading advocate organization for methadone, the National Alliance of Methadone Advocates (NAMA), developed this training, believing that professionals, patients and families of patients can come together to work for a better understanding of methadone and medication assisted treatment. Previous trainings have shown that participants – both professionals and patients alike are equally empowered. Therefore we encourage both patients and non-patients to become Certified Methadone Advocates (CMA). This training is designed for non-clinicians and provides a basic understanding of the physiology of addiction and the use of medications to treat it (i.e. methadone and buprenorphine). Regulations at the federal, state and local levels are explained in simple terms for non-policy makers. Participants will come away with the initial tools for basic advocacy to grow and develop into successful advocates. The course involves 8 hours of rigorous training and fulfills the training requirement for Certification as a Methadone Advocate (CMA).

With these goals in mind, the course presentation is constituted as follows:

- **Medication Assisted Treatment** – Basic clinical information about methadone and buprenorphine treatment.
- **Addiction and Methadone** - Current science about addiction in a language understandable to the non-clinician.

- **Regulations and Accreditation** – Current regulations explained by the federal agency that oversees methadone and buprenorphine treatment.
- **State Methadone Authority** – New York State regulations explained by the NY SMA provide a view of working within state systems.
- **Hands On Advocacy** – Basic tools to work as an advocate and how to manage simple issues that advocates are confronted with including educating patients about their rights, handling grievances, legal issues and working within communities to benefit patients and treatment.
- **Advocacy and The Media** – Responding to negative media in newspapers, television, movies, etc. and writing response letters and letters to the editor.
- **Systems Advocacy** – Using advocacy to change policy and working within state and federal systems to improve the rights of patients.
- **Advocacy Campaigns** – Developing an advocacy campaign to target an issue or respond to negative and incorrect information about medication assisted treatment.
- **The Certified Methadone Advocate (CMA)** – What is a Certified Methadone Advocate, ethics of advocacy and the mechanism of certification and how it will professionalize those committed to advocacy.

Candidates for certification must register with NAMA prior to the conference. On-site registration will be between 8:00am and 9:00am at the NAMA table in the foyer of the Nassau Suite. NAMA cannot guarantee a place to anyone who did not pre-register.

There is a separate registration fee of \$50.00 for this pre-conference event. The fee includes all materials, 2008/09 membership in NAMA, and the application for CMA. Lunch is not provided.

**Sponsored by the National Alliance of Methadone Advocates (NAMA).**



## PRE-CONFERENCE SESSIONS Saturday, April 25, 2009

### 8:00 AM - 5:30 PM *Beekman Parlor & Sutton North* **Buprenorphine and Office-Based Treatment of Opioid Dependence**

*Edwin A. Salsitz, MD, Beth Israel Medical Center, New York, NY*

*Petros Levounis, MD, The Addiction Institute of New York, St. Luke's & Roosevelt Hospitals; Columbia University College of Physicians & Surgeons, New York, NY*

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV and V narcotic medications for the treatment of opioid addiction in an office-based setting as part of the Drug Abuse Treatment Act (DATA) 2000.

Physicians qualify after completion of not less than eight (8) hours of approved training. This course satisfies the DATA 2000 eight-hour training requirement. Certificates will be provided to each physician who completes the training confirming the eight hours of training. Certificates may be mailed to the Secretary of Health and Human Services along with a Request for Waiver of the special registration requirements defined in the Controlled Substances Act.

The goal of this program is to acquire the knowledge and skills needed to provide optimal care to opioid dependent patients.

Topics covered in the program are:

- Overview of opioid dependence: describes the rationale and effectiveness of opioid pharmacotherapy in the treatment of opioid dependence.
- Buprenorphine efficacy and safety: summarizes the literature on the efficacy and safety of buprenorphine treatment.
- Legislative changes: summarizes the law, Drug Addiction Treatment Act of 2000 (DATA 2000), that allows for the treatment of opioid dependence in office-based settings.
- Patient selection: describes the essential aspects of assessing and selecting patients appropriate for office-based opioid treatment.
- Clinical use of buprenorphine: describes induction, stabilization and maintenance protocols for treating opioid dependent patients with buprenorphine.
- Non-pharmacological interventions: describes the efficacy, components and role for non-pharmacological treatments for opioid dependence.
- Medical and psychiatric conditions in opioid dependent patients: summarizes the common medical and

psychiatric co-morbidities including HIV/AIDS, hepatitis B and C, depression and anxiety found in opioid dependent patients.

- Special treatment populations: describes the management of pain in patients with addictive disorders, and the management of adolescents and pregnant women with opioid dependence.
- Office procedures: describes and be able to apply clinical tools (e.g. treatment contracts, consents and protocols) needed to set up office-based treatment with buprenorphine. Describes the important confidentiality and record keeping requirements for treating opioid dependent patients in office-based settings.

This program is recommended for physicians with experience and/or interest in treating opioid dependence. This program features didactic and case-based small group discussions. It is also recommended for primary care, psychiatric, HIV, pain and addiction medicine physicians.

There is a separate registration fee for this session. Please register on-site at the ASAM Registration Desk.

**Sponsored by the American Society of Addiction Medicine. Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.**

### 8:30 AM - 5:00 PM *Sutton Center & South* **Performance Improvement in Opioid Treatment**

*Robert A. Johnson, MEd, DB Consulting, Columbia, MO*

*Brenda Gilliam-Jones, MPA, DB Consulting/Johnson, Bassin and Shaw, Inc., Orlando, FL*

#### **Module One - Introduction to the Workshop:**

The purpose of this module is to conduct an overview of the workshop and to set the tone for the training by creating a positive environment for discussion and for learning about performance improvement in opioid treatment facilities.

#### **Module Two - What Is Performance Improvement?**

The goal of this segment of the workshop is to create a common understanding of the terms and definitions that are used in the field of performance improvement and that will be used during the workshop.

#### **Module Three - Developing an Organizational Culture for Performance Improvement**

The purpose of this module is to review the type of organizational culture required to plan and implement an effective, comprehensive performance improvement system.

## PRE-CONFERENCE SESSIONS Saturday, April 25, 2009

### Saturday, April 25, 2009

#### Performance Improvement in Opioid Treatment (continued)

##### Module Four - Using Outcome Studies in PI Programs

The goal of this module is to discuss the benefits and challenges of examining existing outcome studies in the opioid treatment field and to explore how to develop clinic- or program-based OTP outcome studies.

##### Module Five - The 12 Steps of the Performance Improvement Process

The purpose of this module is to facilitate, review, and discuss the key elements of an effective performance improvement process. The module will also include strategies for addressing some of the challenges organizations encounter in PI programs including data collection and analysis, writing outcome measures, and evaluating plan effectiveness.

##### Module Six - Planning to Move Forward

The purpose of this session is to bring the participants together to review lessons learned during the training, to discuss how they will apply those lessons in their own organizations, and to develop specific action plans to address performance improvement needs in their organizations.

##### Module Seven - Workshop Closing Activities

This section of the workshop will include a summary of the day's training, a review of participant expectations, and completion of participants' workshop evaluation forms.

**Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

3:00 PM - 5:00 PM

*Murray Hill B*

#### The Physician Clinical Support System - Improving Office Based Care of Opioid Dependence

*David Fiellin, MD, Yale University School of Medicine, New Haven, CT*

*Judith Martin, MD, The 14th Street Clinic, Oakland, CA*

*James Egan, MPH, The New York Academy of Medicine, New York, NY*

Office-based treatment of opioid dependence with buprenorphine is a new practice in American medicine. Most U.S. physicians have not had extensive training nor the opportunity to provide this type of care. The federally mandated 8 hour courses that are required for physicians to prescribe buprenorphine, cover the treatment of opioid dependence but may leave questions unanswered. The Physician Clinical Support System (PCSS) is a federally (CSAT) funded program, administered by ASAM, in conjunction with AATOD, primary care, pain, psychiatric, HIV and other medical societies, that is designed to provide education and support for physicians who offer office-based treatment of opioid dependence with buprenorphine. This workshop will describe the current status of buprenorphine training and treatment in the U.S., describe the PCSS, its goals, make-up, services, and resources, including more than 3000 participants and 83 physician mentors who constitute the program. We will describe the specialized services including internet, email, telephone and on-site services that have been developed to improve the quality of care that is provided for opioid dependent patients. We will present data and describe PCSS resources on buprenorphine induction, counseling, buprenorphine dosing, payment and reimbursement, hepatitis, adherence, diversion and HIV - issues that confront physician practices as they begin to provide office-based care for opioid dependent patients.

**Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

## AATOD OPEN BOARD MEETING

*Regent Parlor*

Saturday, April 25, 2009 • 5:00PM – 8:45PM

## PRE-CONFERENCE SESSIONS Sunday, April 26, 2009

### Sunday, April 26, 2009

**8:00 AM - 5:30 PM** *Rendezvous Trianon*

#### Opioid Maintenance Pharmacotherapy: A Course for Clinicians

Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA

Susan Neshin, MD, JSAS Healthcare, Inc., Asbury Park, NJ

J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL

Trusandra Taylor, MD, NETSTEPS, ACT I AND II, Philadelphia, PA

This course is recommended for clinicians with experience and/or interest in medication assisted treatment of opioid dependence. This program provides basic and state of the art information. The curriculum is updated to include current consensus guidance for best practice treatment for opioid addiction. Topics include overview of opioid dependence, epidemiology, opioid pharmacology/neurobiology; evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone mortality, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management and an overview of buprenorphine.

Participants will receive a comprehensive syllabus with reference and resource materials. The curriculum will include relevant case study discussion with audience participation to facilitate the learning process. To further integrate the educational objectives, participants are encouraged to discuss challenging problems and clinical issues to facilitate understanding of didactic principles.

Four experienced opioid treatment medical directors will conduct the program, focusing on the goal for participants to acquire the essential knowledge and skills necessary to deliver safe and effective medication assisted treatment for patients with opioid dependence.

The \$150.00 registration fee includes a morning coffee service, afternoon luncheon and the evening's welcome reception. On-site registration can be done at the AATOD registration desk.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. and American Society of Addiction Medicine in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the National Institute on Drug Abuse.

**8:30 AM - 12:30 PM**

*Nassau Suite*

#### Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Frank J. Carillo, ECG, Inc., Englewood, NJ

Dan McGill, McGill Consulting, Brooklyn, NY

Opioid treatment programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately to operate in the best interests of our patients and communities.

This workshop teaches three key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication-assisted treatment (MAT). These messages resulted from a year-long pilot project entitled "Communicating Messages That Achieve Results". Providers will hear these messages and learn how to communicate them in order to create a positive impact within their communities. The workshop will include Q & A techniques designed to deal with emotionally charged audiences while reinforcing the presenter's objective.

This is an updated workshop that premiered at the 2006 Atlanta Conference and was repeated by popular demand in San Diego in 2007. MAT advocates using this approach have been very successful, hence another chance to experience this training!

Sponsored by The American Association for the Treatment of Opioid Dependence, Inc.

Supported by VistaPharm, Inc.

### WELCOME RECEPTION

*Grand Ballroom Promenade*

**Sunday, April 26, 2009**

**5:30 PM – 7:30 PM**

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long.

Supported in part by:  
Addiction Treatment Providers Insurance Program



## PRE-CONFERENCE SESSIONS Sunday, April 26, 2009

**9:00 AM - 12:00 PM** *Beekman Parlor & Sutton North*

### Opioid Treatment Program Accreditation - Town Hall Meeting

Megan Marx, MPA, *The Joint Commission, Littleton, CO*

Mary Cesare-Murphy, PhD, *The Joint Commission, Oakbrook Terrace, IL*

This session is designed to be an open forum for Joint Commission accredited programs to discuss accreditation questions, concerns & challenges. Presenters will provide an overview of OTP accreditation to date. Topics expected to be covered include:

- Changes in the scoring & decision making process
- Changes in the CAMBHC – Leadership Chapter
- Robust Process Improvement

Presenters will split the two hour presentation time equally, allowing for Q&A throughout the presentation.

#### Workshop Objectives

At the end of this workshop participants will be able to:

1. Understand changes made in the scoring & accreditation decision making process & how they may affect their program.
2. Understand changes made in the CAMBHC Leadership chapter, & how to implement these changes in their program.
3. Discuss robust process improvement & identify where it may apply to their program.

Registration for this workshop is open to all Joint Commission Accredited Treatment Programs. To register on-site, please visit the Joint Commission Registration Desk.

**Sponsored by The Joint Commission.**

**9:00 AM - 5:30 PM** *Sutton Center & South*

### State Opioid Treatment Authorities' Meeting (Closed Session for State and Federal Officials)

Robert Lubran, MS, *Center for Substance Abuse Treatment, Rockville, MD*

Nicholas Reuter, MPH, *Center for Substance Abuse Treatment, Rockville, MD*

Sara Azimi-Bolourian, *Center for Substance Abuse Treatment, Rockville, MD*

Mary Lou Ojeda, *Center for Substance Abuse Treatment, Rockville, MD*

Alina Walizada, *Center for Substance Abuse Treatment, Rockville, MD*

Jennifer Fan, *Center for Substance Abuse Treatment, Rockville, MD*

Denise K. Curry, JD, *Drug Enforcement Administration, Arlington, VA*

*State Opioid Treatment Authorities*

Center for Substance Abuse Treatment staff and State Opioid Treatment Authorities will convene to discuss a variety of topics of interest to both Substance Abuse and Mental Health Services Administration (SAMHSA) and the states.

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

*\*Please Note: Session is not approved for CME.*

**9:30 AM - 12:00 PM**

*Regent Parlor*

### Opioid Analgesics and Pain in Opioid Dependence Treatment - New Research Findings, Clinical Implications

Petra Jacobs, MD, *Clinical Trials Network, NIDA, Rockville, MD*

Roger Weiss, MD, *Harvard Medical School, Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA*

Jennifer Sharpe Potter, PhD, *Harvard Medical School, Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA*

Deborah Haller, PhD, *Columbia University College of Physicians & Surgeons, St. Luke's Roosevelt Hospital Center, NY*

Steven Passik, PhD, *Memorial Sloan Kettering Cancer Center, NY*

The Clinical Trials Network (CTN) is an important program of the National Institute on Drug Abuse (NIDA) focused on the design and implementation of clinically relevant studies in the field of drug addiction treatment research. It consists of sixteen geographically diverse "Nodes" centered in key academic institutions, partnering with local Community Treatment Programs (CTPs). Since 1999, CTN has served as NIDA's primary vehicle for blending the interests of research and practice and improving drug abuse treatment through science. This includes the Prescription Opioid Addiction Treatment Study and other initiatives focused on prescription opioid addiction and chronic pain.

**(Continued on page 8)**

## PRE-CONFERENCE SESSIONS Sunday, April 26, 2009

*Continued from Page 7*

Many people with prescription opioid dependence have chronic pain, and there is also a substantial overlap with the use of heroin. The first presentation will focus on decisions that were made in order to define prescription opioid population in the Prescription Opioid Addiction Treatment Study, the largest and most comprehensive opioid analgesic dependence treatment study to be conducted so far, to produce a study population that was both distinct and new but also representative of patients seeking treatment in the community. Furthermore, the presentation will show previously unexamined characteristics of individuals presenting specifically for opioid analgesic dependence treatment.

The second presentation will highlight the issues facing substance abuse clinicians who are treating opioid dependent patients with chronic non-cancer pain. The presentation will review preliminary data from a treatment study designed to address pain and addiction concurrently, and will raise issues related to the use of methadone vs. buprenorphine vs. commonly abused opioid analgesics such as hydrocodone or oxycodone for treating co-occurring pain and opioid addiction.

The third presentation will describe recent information on how to assess and address aberrant drug taking behaviors during pain management. Furthermore, a detailed description of issues related to pain management in patients with opioid dependence and strategies for how to address this will be presented.

**Supported by the National Institute on Drug Abuse and the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN).**

**1:00 PM - 4:00 PM**

**Nassau Suite**

### Risk Management in the OTP

*Catherine H. O'Neill, JD, Legal Action Center, New York, NY*

*Alan Wartenberg, MD, Tufts University, Boston MA;  
Opioid Treatment Program, Providence VA Medical  
Center; Providence, RI*

Health care risk management programs emerged 30 years ago and were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that opioid treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. Accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management.

This session will introduce OTP administrators to the key elements of a risk management program and how they can be directly applied to OTPs. Attendees will also get the most current information available about leading legal risks to OTP operations in addition to a discussion of some critical court cases that have recently affected OTPs. Topics to be covered include:

- Risk management basics:
  - ♦ What happens to the program when adverse events occur
  - ♦ Scope of risk management
  - ♦ Common risk identifiers
  - ♦ Setting priorities
  - ♦ Risk prevention and minimization
  - ♦ Claims management
- Existing and emerging medical, clinical and legal standards of care for OTPs:
  - ♦ The role that accreditation, certification, regulatory and clinical practice guidelines play in setting standards of care for OTPs
  - ♦ Recent negligence/malpractice lawsuits and related legal developments involving OTPs and their patients
- Developing protective medical, clinical and legal strategies to deal with common legal and liability risks, including:
  - ♦ Patient induction, dosing and monitoring issues
  - ♦ Impaired driving concerns
  - ♦ Assessing and addressing complex needs: patients with co-occurring disorders; continuing substance use; other complicating factors
  - ♦ OTPs' liability for patients' actions

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.**

**Supported by Substance Abuse Mental Health Services Administration, Center for Substance Abuse Treatment.**

**1:00 PM - 5:00 PM**

**Regent Parlor**

### Hepatitis Education for Opioid Treatment Providers

*Susan Simon, Hepatitis C Association, Scotch Plains, NJ*

*Bruce Burkett, Hepatitis C Association,  
Missouri Hepatitis C Alliance, Columbia, MO*

*Betsy Ingram-Diver, Hepatitis C Association,  
Lake Superior College, Duluth, MN*

*Patty Gilbert, Hepatitis C Association, Hampton-Newport  
News Community Services Board, Hampton, VA*

*David Fiellin, MD, Yale University School of Medicine,  
New Haven, CT*

*Jeanette Tetrault, MD, Yale University School of Medicine,  
New Haven, CT*



## PRE-CONFERENCE SESSIONS Sunday, April 26, 2009

Hepatitis C Virus (HCV) is considered the most common blood-borne infection in the United States. There are approximately 5 million people infected. Injection drug use accounts for more than two-thirds of all new infections in the United States. OTPs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmissions.

This updated session will provide the most recent information on hepatitis A, B and C, diagnosis, transmission, risk factors, screening, diagnostic testing, referral, treatment, new drugs in trial, healthy behaviors, counseling issues and barriers to care.

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.**

**Supported by Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

### 1:00 PM - 5:00 PM *Beekman Parlor & Sutton North*

#### Trends and Changes in the Quality Framework called "Accreditation"

*Bettye Harrison, CARF International, Tucson, AZ*

*Darren Lehrfeld, CARF International, Tucson, AZ*

This session is designed to provide a discussion of the changes occurring in the framework of accreditation. Starting this year, CARF International has reorganized its standards into a model we hope will help CARF-accredited organizations to better meet the demands of the modern health and human services environment. The growing demands of the environment require opioid treatment programs to focus their time and resources on strategies to ensure quality service provision. The reorganization of the CARF Business Practice Standards into the *ASPIRE to Excellence™* model demonstrates CARF's continued commitment to assisting its accredited organization in navigating this changing environment.

The session will focus on:

- An overview of quality standards
- Trends in the provider environment and standard conformance
- Continuous improvement strategies to position organizations for continued success

**Sponsored by the Commission on Accreditation of Rehabilitation Facilities (CARF).**

### 1:00 PM - 5:00 PM

*Petit Trianon*

#### European Opiate Addiction Treatment Association (EUROPAD): Heroin Addiction and Related Clinical Problems

*Chairmen: Icro Maremmanni, MD, Pisa, Italy, EU*

*Marc Reisinger, MD, Brussels, Belgium, EU*

- 1:00 PM** Efficacy of Opioid Agonist Therapy on Psychopathological Symptoms: Methadone vs Buprenorphine  
*Icro Maremmanni (Pisa, Italy, EU)*
- 1:20 PM** Repressive Strategy Against Liberal Strategy in Treating Heroin Addicts in Russia  
*Vladimir Mendelevich (Kazan, Russia)*
- 1:40 PM** Economic Evaluation of Interventions To Treat Opiate Dependence: A Review of the Evidence  
*Christopher M. Doran (Sydney, Australia)*
- 2:00 PM** The European Experience Delivering Buprenorphine and Methadone. Comparison Between France and Portugal (regulations, clinical experience, practice)  
*Pascal Courty (Clermont-Ferrand, France, EU), Luis Patricio (Lisbon, Portugal, EU) and Didier Touzeau (Paris, France, EU)*
- 2:20 PM** Fundamental Principles and Rules in Treating Heroin Addicts at "Fondation Phenix" in Geneve, Switzerland  
*Michel Bourquin and Jean-Marie Rossier (Geneve, Switzerland)*
- 2:40 PM** Screening and Treatment of Viral Hepatitis B and C in Inmates With and Without Opioid Agonist Therapy. Results of Four French National Surveys (2000-2005)  
*Andre-Jean Remy (Perpignan, France, EU)*
- 3:00 PM** What Treatment is Good Treatment? Clinician's Reflections on Patient Perspectives  
*Alexander Kantchelov, Tsvetana Stoykova, Orlin Todorov and Alexander Belchev (Sofia, Bulgaria, EU)*
- 3:20 PM** Heroin Addiction and Mortality  
*Barbara Lovrecic and Mercedes Lovrecic (Ljubljana, Slovenia, EU)*
- 3:40 PM** Opioid Maintenance Therapy (OMT) and Cardiac Arrhythmia. Mortality Assessment in a Norwegian National Registry Study  
*Thomas Clausen, Katinka Anchersen & Helge Waal (Oslo, Norway)*
- 4:00 PM** Treating Heroin Addicts in Jail  
*Andrej Kastelic (Ljubljana, Slovenia, EU)*
- 4:20 PM** Opiates and Alcohol. Important Clinical Connections  
*Albrecht Ulmer (Stuttgart, Germany, EU)*
- 4:40 PM** Discussion
- 5:00 PM** End of Forum

**In collaboration with EUROPAD-Italia and Italian Society of Addiction Medicine (SITD)**

*\*Please Note: Session is not approved for CME.*

## EXHIBIT AND POSTER SESSIONS

## Rhineland Gallery

**Sunday, April 26 2:00PM – 5:00PM**

**Monday, April 27 7:30AM – 4:30PM**

**Tuesday, April 28 7:30AM – 1:30PM**

*Posters are in place at all times when the exhibit hall is open*

*Authors will present their topic on Tuesday, April 28th from 7:30AM – 8:45AM.*

**P 101 For More Effective Treatment & Better Outcome**

*Mercedes Lovrecic, MD*

**P 102 Cultural Factors Impacting Compliance of African Americans in Opioid Treatment Programs**

*Arthur L. Burnett, Sr., LL.B.*

**P 104 Reproductive Recovery: The Mommies Program A Collaborative Relationship Between Choices Recovery Program Methadone Clinic and Luzerne County Children and Youth Parenting Center**

*Sandra Ancas, MSW*

**P 105 Post-Traumatic Stress Disorder and Substance Use Among Women in Methadone Maintenance Clinics: Screening, Staff Training and Treatment**

*Shabtay Levit, MSW*

**P 106 Accreditation Standards Improvement Initiative**

*Megan Marx, MPA*

**P 107 Recovery Focused Care: Medication Assisted Recovery is More Than Just Medication**

*Roland C. Lamb, MA*

**P 108 Starting Treatment with Agonist Replacement Therapy: The START Study: The Community Treatment Provider's Experience**

*Allan J. Cohen, MA*

**P 109 Rapid Growth, Rapid Change: Growing High Integrity Programs through Effective Management and Vision**

*Brent Scobie, MSW*

**P 110 Beyond Medication: Integrating Psychotherapies in OTP**

*Alexander Kantchelov, MD*

**P 111 HIV Prevention Interventions Targeting the Problem of Engaging in Sex under the Influence of Drugs and Alcohol while in Substance Abuse Treatment**

*Donald Calsyn, PhD*

**P 112 Comprehensive Methadone Treatment as HIV Prevention: Implementation and Scale-up of Methadone Treatment in Vietnam as a Government of Vietnam/PEPFAR Collaboration**

*Lynn Sullivan, MD*

**P 113 Medication Assisted Recovery and Support: A 12 Step Fellowship Program for the Medication Assisted Patient in Recovery**

*Ralph "Bo" B. Waddell, III, AS*

**P 114 OTP Treatment Experience Among Incarcerated Men in Puerto Rico**

*Begoña Rivera, PsyD*

**P 115 Outcome Study of the Living Skills Recovery Curriculum with Opioid Dependent Mentally Ill Clients**

*Pat J. Precin, MS*

**P 116 The Road Less Traveled: Client Utilization of a Methadone-to-Abstinence Residential (MTAR) Therapeutic Community Program in NY**

*Janetta Astone-Twerell, PhD*

**P 117 Patient Safety In Opioid Addiction Treatment - A Survey of OTP Training in Pennsylvania**

*Trusandra E. Taylor, MD*



## EXHIBIT AND POSTER SESSIONS

## Rhineland Gallery

### P 118 Boston's OTP Journey from 1972-2009

*Paul E. Bowman, BA*

### P 119 Mortality Report Form

*Alina Walizada, MS*

### P 120 The New Strategies of Harm Reduction Project on Drug Prevention in Taiwan

*Jih-Chiao Chu*

### P 121 Survey Analyses for Implementing an Electronic Information System to Enhance Practice at an Opioid Treatment Program

*Steven Kritz, MD*

### P 122 Katrina and Rita - Two + Years Later

*Jane C. Maxwell, PhD*

### P 123 One Stop Shop Model of Treatment and Care Model for Street Drug Users

*Bijan Nassirimanesh, MD*

### P 124 Gender Differences in Methadone Maintenance Treatment Outcome

*Liljana A. Ignjatova, MD*

### P 125 Psychiatric and Substance Use Correlates of Physical Pain in Methadone Maintenance

*Declan T. Barry, PhD*

### P 126 HAART Use in an Integrated Suboxone/HIV Primary Care Program

*Helen G. Loewenthal, MSW*

### P 127 Smoking Cessation Program in a Methadone Maintenance Program

*Lewis E. Galaway, MA*

### P 128 Work Matters: The Importance of Integrating Vocational Rehabilitation Services to Improve Treatment Outcomes

*Michele Buoninfante, MA*

### P 129 Buprenorphine Maintenance in Jail and at Post-Release

*Andrew Rosenblum, PhD*

### P 130 Buprenorphine: A Guide for Nurses

*Sara Azimi-Bolourian, MSN*

### P 131 Opioid Addiction Treatment Modalities in Ukraine. Availability and Challenges

*Nataliya Vlasova, MA*

### P 132 Former Heroin Addicts Currently in Methadone Maintenance Treatment (MMT) with Axis I & II Psychiatric Diagnosis Presented Best Cumulative Retention Compared to no Axis I and no Axis I & II Groups

*Einat Peles, PhD*

### P 133 Observational Studies and Follow-Up of Patients in Treatment with Olanzapine and Substitutive Drug

*Maria Chiara Pieri, MD*

*\*Please Note: Posters are not approved for CME credit.*

## CONFERENCE SESSIONS **Monday, April 27, 2009**

### CONFERENCE OBJECTIVES

The goals and objectives of the 2009 American Association for the Treatment of Opioid Dependence, Inc. National conference are:

- Identify and provide to the target audience new information of critical concern to the field of treatment for opioid addiction
- Provide a forum for analyzing and evaluating the implications of new information
- Demonstrate and provide opportunities for participants to practice approaches and techniques for improving clinical services and administrative functioning.

**7:30AM**

**Rhineland Gallery**

**Continental Breakfast**

Sponsored by Netsmart Technologies

### OPENING PLENARY SESSION

**8:45AM – 10:15AM**

**Grand Ballroom**

#### Meeting Challenges In Turbulent Times: New York State's Transformed Treatment System and Continuum of Care



##### Welcome and Introductions

*Ira J. Marion, MA, Conference Chairperson,  
2009 Director, Government Relations  
and Public Policy, Albert Einstein College  
of Medicine*



##### The State of the Field: Meeting Challenges in Turbulent Times

*Mark W. Parrino, President, American  
Association for the Treatment of Opioid  
Dependence, Inc.*



##### Transforming Methadone Treatment in New York State

*The Honorable Karen M. Carpenter-Palumbo,  
Commissioner, New York State Office of  
Alcoholism and Substance Abuse Services*

The Opening Plenary will focus on the significant challenges facing our field. Conference Chairperson, Mr. Ira J. Marion, will open the conference by welcoming attendees to New York City and will provide an overview of the conference. Mr. Marion will also discuss the implications of the repeal of the Rockefeller Drug Law in New York State and its impact on increasing access to treatment for opioid dependent individuals. Mr. Mark Parrino, AATOD President, will present an overview of the challenges facing OTPs in the United States and AATOD's initiatives to

respond to these changing dynamics now and into the future. Conferees will hear from New York State's Commissioner of Alcoholism and Substance Abuse Services, Karen M. Carpenter-Palumbo, whose energy and commitment will motivate all in attendance. Early in her tenure as Commissioner, Ms. Carpenter-Palumbo saw the need for a plan to transform New York's OTP system, reforming regulations, taking OTPs out of the "silo," and making them full partners in the prevention, treatment and recovery continuum in New York State, the largest system in the nation. Commissioner Carpenter-Palumbo will outline New York's transformation plan for OTPs.

*\*Please Note: Session is not approved for CME from ASAM.*

### 10:30AM – 12:00PM **Workshop Sessions**

Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

**Basic Track:** This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend ALL six sessions listed will receive a special certificate of completion. **Basic Track Workshop Sessions:** A1, B1, C1, D1, E1 and F1

#### **A1**

**Mercury Ballroom**

##### Medical Issues for Counselors: Four Patient Questions About Methadone

*Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA*

This workshop introduces the medical model of addiction, and reviews questions commonly asked by patients about the medication itself. Why is methadone better than using heroin? How do I know I'm taking the right dose? How long should I stay on methadone maintenance? What are the side effects of methadone? Counselors use this information in their therapeutic alliance with the patient who is enrolled in methadone maintenance.

*\* Note: Basic Track*



## CONFERENCE SESSIONS **Monday, April 27, 2009**

- A2** *Nassau Suite*  
**How to Effectively Communicate Research and Policy Recommendations to Key Decision-Makers**  
*Jenny Collier, JD, Independent Advocacy and Policy Consultant, Washington, DC*  
 Opioid-based treatment is one of the best-researched addiction treatments in the world, but policy makers continue to doubt its effectiveness. Such misunderstanding reduces funding for and stalls implementation of important opioid treatment policies. In this workshop, researchers, providers and advocates will improve their ability to translate opioid treatment research and practice into concrete policy recommendations. Participants will gain tools to effectively communicate these recommendations to local, state, and federal decision-makers.
- A3** *Trionon Ballroom*  
**Staff Training and Program Implementation of an Evidence-Based Treatment for Co-Occurring PTSD in Community OTPs**  
*Mark P. McGovern, PhD, Dartmouth Medical School, Lebanon, NH*  
*Phil F. Richmond, MS, Hartford Dispensary, Hartford, CT*  
*Aliza Castro, MSW, Hartford Dispensary, Hartford, CT*  
 This workshop describes the development and implementation of a simple, practical evidence-based practice, cognitive behavioral therapy, for patients in methadone maintenance, for one of the most vexing co-occurring psychiatric disorders: Posttraumatic Stress Disorder (PTSD). There will be a description of the outcomes of this project along with lessons learned, challenges and recommendations for implementation in other settings. New data, from a randomized controlled trial comparing the CBT with individual addiction counseling, will also be presented.
- A4** *Beekman Parlor & Sutton North*  
**From Conception to Postpartum: Update of Methadone During the Perinatal Period**  
*John McCarthy, MD, Bi-Valley Medical Clinic, Sacramento, CA*  
*Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD*  
*Karol Kaltenbach, PhD, Thomas Jefferson University, Philadelphia, PA*  
 This workshop focuses on three issues. The first presentation reports on outcomes of neonates born to women who conceived and are maintained on methadone throughout pregnancy; the second reviews data supporting the current USA clinical guidelines regarding medication assisted withdrawal during pregnancy; and the third presents the results of a retrospective study tracking maternal dose at the beginning of the third trimester, changes across the third trimester, dose at delivery, and dose changes throughout six (6) weeks postpartum.
- A5** *Sutton Center & South*  
**Philadelphia Prison Experiment: 10 Years of MAT Within a Correctional Setting on a Limited Budget**  
*John T Carroll, NCAC II / CCS, Northeast Treatment Centers, Philadelphia, PA*  
*Roland Lamb, MA, Philadelphia Department of Behavioral Health, Philadelphia, PA*  
 Over the past 10 years, an evolutionary collaboration has developed for the management of methadone maintained inmates incarcerated within the Philadelphia Prison System. The treatment model evolved from short term methadone detoxification into a state-of-the-art treatment program providing methadone maintenance to 400+ inmates a year with innovative re-entry services yielding extraordinary outcomes. The program design successfully incorporates the culture, factors and forces of a correctional environment to deliver comprehensive cost effective MAT.

**THE POLICY MAKER'S LUNCHEON**  
**on Monday, April 27, 2009 is**  
*supported through a grant from Bendiner & Schlesinger, Inc.*

## CONFERENCE SESSIONS Monday, April 27, 2009

### 1:30PM – 3:00PM Hot Topic Round Tables

Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

- **Discharges for Financial Reasons** *Gibson Suite*  
Facilitators: Dana Moulton, CMA and Ron Jackson, MSW
- **Smoking Cessation in MAT** *Holland Suite*  
Facilitator: Caroline Waterman
- **Disaster Planning in OTPs** *Lincoln Suite*  
Facilitator: Arlene Stanton, PhD
- **OD Prevention in OTPs** *New York Suite*  
Facilitator: Randy Seewald, MD
- **Aging Issues** *Midtown Suite*  
Facilitator: Carolyn Drennan
- **Driving Safety** *Rendezvous Trianon*  
Facilitator: Catherine H. O'Neill, JD

\*Please Note: Hot Topic Sessions are not approved for CME by ASAM.

### 1:30PM - 3:00PM

#### #1 Beekman Parlor & Sutton North

#### Integrating Routine Domestic Violence Assessment and Intervention into Opioid Dependency Settings

Monica Joseph, PhD, Addiction Research and Treatment Corporation, New York, NY

Michelle Melendez, MSW, Addiction Research and Treatment Corporation, New York, NY

Melissa Mei-Yu Lin Chu, MS, Addiction and Research Treatment Corporation, New York, NY

This presentation will address the research findings related to the prevalence of substance abuse and domestic violence, as well as attitudes and perceptions of staff in opioid dependency programs and domestic violence settings. A current model for assessing domestic violence within substance abuse settings and substance abuse within domestic violence settings will be described. Concrete strategies for addressing the knowledge, attitudes/values and skills needed for corresponding interventions will be presented. Variables that should be integrated into developing a seamless resource network will also be examined.

### #2

#### Sutton Center & South

#### Electronic Health Records and Opioid Treatment Programs

Nicholas P. Reuter, MPH, Substance Abuse and Mental Health Services Administration, CSAT, Rockville, MD

Mary Murphy, Veterans Affairs Hospital OTP, Washington, DC  
David Picolli, Discovery House, Providence, RI

The use of electronic health recordkeeping will continue to expand in the coming years. This workshop will highlight two OTP systems that have complete electronic health records (EHR). A CSAT representative will discuss how EHRs align with Federal recordkeeping requirements. Participants will understand the challenges of establishing a system, together with the reimbursement and other advantages tied to EHRs.

Audiovisual support provided by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

### #3

#### Nassau Suite

#### Methadone Maintenance and the Child Welfare System: What We Know and What We are Learning

Steve Hornberger, MSW, National Association for Children of Alcoholics, Silver Spring, MD

Patti Juliana, MSW, Beth Israel Medical Center, New York, NY

Naomi Weinstein, MPH, Center on Addiction and the Family, Phoenix House, New York, NY

This session will address developing collaborative relationships between the child welfare system and methadone programs, improving outcomes for families and increasing family involvement as a combined effort. Presenters will discuss a cross system training initiative in New York City, resources to help patients and family members and share one agency's change process to partner with the child welfare system.

## EXHIBITOR NETWORKING BREAK

### Rhineland Gallery

Monday, April 27, 2009 3:00PM – 4:00PM

Sponsored in part by O. Berk Kols Container Inc. and Tower Systems, Inc.



## CONFERENCE SESSIONS Monday, April 27, 2009

4:00PM – 5:30PM

### Workshop Sessions

#### B1

#### Mercury Ballroom

### Alcohol Abuse in Methadone Maintenance Patients: Understanding and Addressing a Serious Problem

Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment (BAART), Sherman Oaks, CA

Adeline Nyamathi, PhD, UCLA School of Nursing, Los Angeles, CA

Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

This workshop presents the problem of alcohol abuse in agonist-maintained patients including a review of prevalence rates across populations with differing demographics as well as evidence-based outcome of treatment interventions. We will explore a variety of alcohol-related clinical issues faced by treatment providers and discuss how these issues are addressed in the OTP setting. A description of findings from an NIAAA-funded research study using motivational interviewing will be presented.

\* Note: Basic Track

#### B2

#### Trianon Ballroom

### Peer-to-Peer Recovery Services in MAT: Early Lessons from the MARS Project

Joycelyn S. Woods, MA, National Alliance of Methadone Advocates (NAMA), New York, NY

Jo L. Sotheran, PhD, National Alliance of Methadone Advocates (NAMA), Brooklyn, NY

Howard S. Lotsof, BFA, National Alliance of Methadone Advocates, Dora Weiner Foundation, Staten Island, NY

Peer-to-peer recovery support services are in their infancy in MAT, although well established in other treatment modalities. The National Alliance of Methadone Advocates was awarded the first MAT project within CSAT's Recovery Community Services Project. The Medication Assisted Recovery Services (MARS) project, with its central vision of a completely peer-based project, is now in its second year. This presentation will describe three aspects of the program, and how they have evolved since the program began, with particular attention to the effects of being embedded in MAT.

#### B3

#### Beekman Parlor & Sutton South

### Expansion of Buprenorphine Treatment for Opioid Dependence into Community Settings: A State-Funded Best Practice Model

Colleen LaBelle, RN, Boston University Medical Center, Boston, MA

Hilary Jacobs, MSW, Bureau of Substance Abuse Services, MA Department of Public Health, Boston, MA

This workshop will highlight a best practice model that allowed for the expansion of buprenorphine treatment in Massachusetts providing training, technical support, and nurse care managers to 20 community sites with State funding. The model addressed barriers to treatment by providing clinical and technical support to physician providers in community settings. This innovative demonstration project has allowed for the expansion of opioid treatment into primary care practice setting while requiring integration with behavioral health care.

#### B4

#### Sutton Center & South

### Consideration of Cognitive Disabilities in the Treatment of Opioid Dependence

Frank R. Sparadeo, PhD, Informed Interventions, LLC, East Greenwich, RI

Cognitive impairments can occur directly from substance abuse or from other causes such as developmental disability or traumatic brain injury. This workshop has been developed to introduce substance abuse counselors to the process of identifying and treating individuals with co-occurring cognitive disability and substance abuse. This workshop will review normal brain-behavior relationships, the impact of substance abuse on cognitive functioning, how to assess cognitive functioning, and treatment modifications for various types of cognitive impairments.

#### B5

#### Nassau Suite

### Increasing Treatment Retention to Improve Outcomes: Patients' Perspectives

Robert P. Schwartz, MD, Friends Research Institute, Baltimore, MD

Shannon G. Mitchell, PhD, Friends Research Institute, Baltimore, MD

Sharon Kelly, PhD, Friends Research Institute, Baltimore, MD

Through NIDA support, Friends Research Institute and its OTP partners are examining ways to prevent premature discharge. Insights from in-depth interviews of patients discharged from six OTPs; findings from a study of interim methadone treatment as an approach to enhance early treatment retention; and, data from a study of patient satisfaction will be presented. Specific recommendations will be made to increase patient retention through the use of patient perspectives.

## CONFERENCE SESSIONS

### Monday, April 27, 2009

**6:00PM - 8:00PM** *Beekman Parlor & Sutton North*

#### **TOWN HALL: A Continuing Community Discussion of How OTPS and the Treatment Community Can Work Together to Prepare for the Next "Service Discontinuity"**

*Arlene Stanton, PhD, Division for Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT) Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD*

*Walter Ginter, CMA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY*

*Henry Bartlett, BA, Committee of Methadone Program Administrators of New York State (COMPA), New York, NY*

In the aftermath of 9-11, SAMHSA's D-ATM project ("Digital Access to Medication") was conceived as a technological approach to help ensure that OTPs could effectively and safely provide medication to patients who had been displaced from programs where they were normally enrolled. In 2002, SAMHSA/CSAT, working with COMPA and a Steering Committee representing a range of stakeholders, conducted a feasibility and planning study, followed by a smaller developmental study. This confirmed the need for a deliberately simple, web-based, centralized database containing only the information needed by an OTP to verify patients' identity and to provide accurate and safe dosing. In 2005, SAMHSA provided funding to develop the infrastructure for and conduct a limited pilot-test of the system (now known as D-ATM) in 3-4 major metropolitan areas. The purpose of Phase III, recently launched, will be to pursue a national expansion of the system, which promises to provide an important tool for OTPs and a critical means to assure service continuity to patients in treatment for opioid dependence. (More background can be found at the D-ATM website, <http://datm.samhsa.gov/>.)

However, the events of 9-11, Katrina, and many large-and smaller-scale disasters that have followed since the last AATOD conference, have made OTP staff, administrators, and patients all too aware of the kinds of policy issues that can emerge in the wake of disaster, beyond the scope of D-ATM to address.

This Town Hall will begin with a brief overview and status report on D-ATM as Phase III commences, moving to an open discussion of the kinds of disaster preparedness issues that have been encountered in dealing with real-life situations, whether widespread disasters or more routine service disruptions. For instance, how have programs dealt with reimbursement issues or differences in dosing practices, when faced with unfamiliar patients from other programs?

These are complicated issues and it is hoped this Town Hall will provide one means to continue a dialogue among the many members of the treatment community toward identifying which issues still need attention and who best can address them. Representatives of CSAT and other federal and state agencies, members of the D-ATM Steering Committee, and program directors, patients and staff who have had experience in working with DATM or in dealing with disaster first-hand, are especially encouraged to attend.

**Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

### Tuesday, April 28, 2009

**7:30AM**

*Rhineland Gallery*

#### **Continental Breakfast**

**Sponsored by Reckitt-Benckiser Pharmaceuticals, Inc.**

### MIDDLE PLENARY SESSION

**8:45 AM - 10:15 AM**

*Grand Ballroom*

#### **Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes**

**Two Personal Stories of Recovery through Medication Assisted Treatment**



*Anthony Badger  
Union, NJ*



*Carolyn Visconte  
Schenectady, NY*

#### **Medication Assisted Treatment is Recovery**



*William L. White, MA, Senior Research Consultant, Chestnut Health Systems, Bloomington, IL*



**Integrating Recovery Oriented Systems of Care into Medication Assisted Treatment**  
*H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD*

The theme of the Conference "Treatment and Recovery – People and Outcomes" is an effort to urge OTPs to renew their focus on the patients in their treatment programs in



## CONFERENCE SESSIONS Tuesday, April 28, 2009

### Middle Plenary Continued from Page 16

new and more significant ways. Individualized treatment and a renewed focus on outcomes are critical for a recovery plan for each patient. Treatment is always about the people whose lives are changed in different ways and the way they integrate their recovery into the fabric of community life. The integration of MAT and ROSC provides the opportunity to all treatment and recovery providers to identify best practices and desired outcomes to enhance the quality of life for each patient. Renowned recovery pioneer, William L. White, will speak about the growth of the recovery movement this decade and how it has embraced medication-assisted treatment as part of the recovery community. Dr. H. Westley Clark will present the importance of recovery-oriented systems of care in the SAMHSA matrix and will discuss the important new CSAT publication, ROSC in MAT. Most significantly, two patients in long-term recovery through participation in medication-assisted treatment will put a face and voice to their recovery with their compelling and important stories.

**Audiovisual support provided by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

### 10:30AM – 12:00PM Workshop Sessions

#### C1 Beekman Parlor & Sutton North

#### A Guide to Implement a More Recovery Oriented System of Care in Opiate Treatment Programs

*Walter Ginter, Medication Assisted Recovery Support (MARS) Project; National Alliance of Methadone Advocates (NAMA), New York, NY*

*Lisa Mojer-Torres, JD, Faces and Voices of Recovery (FaVoR), Washington, DC*

*Shannon B. Tait, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD*

In May 2008 CSAT convened a panel to create, "A Guide to Introduce and Implement a More Recovery Oriented System of Care in Opiate Treatment Programs". CSAT's charge to the panel stated that in this system, treatment is no more or less important than any other support. This workshop will introduce and explain what a recovery oriented system is, point out problems unique to OTP's in implementing such a system, and suggest possible solutions.

*\*Note: Basic Track*

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

#### C2

#### Sutton Center & South

#### Buprenorphine in the OTP: A Full Spectrum of Options

*Heidi Shah, MD, Spectrum Health Systems, Westborough, MA*  
*Kristin Nolan, MA, Spectrum Health Systems, Worcester, MA*

This workshop will describe four different buprenorphine treatment plans currently being offered by Spectrum Health Systems through several OTP's in Massachusetts. These plans include: 1) outpatient detoxification, 2) induction phase observed treatment with transfer to a community provider for maintenance, 3) observed daily dosing while awaiting transfer to a community provider for maintenance, and 4) maintenance treatment by prescription using a chronic disease model of care.

#### C3

#### Nassau Suite

#### Treatment of Opioid Dependence and ADHD/ADD with Methadone or Buprenorphine and Central Stimulants

*Olof Blix, MD, County Hospital Ryhov, Jonkoping, Sweden*  
*Peter Nilsson, County Hospital Ryhov, Jonkoping, Sweden*

ADHD and ADD together with drug dependence is common. Data at our clinic indicate that 29% of MAT patients also have symptoms of adult ADD or ADHD. Most identified patients report improvements in every day functioning when a central stimulant is added to their daily methadone or high dose buprenorphine medication. Focus will be on diagnostic methods, evaluation, a formalized follow-up protocol, and the every day challenges in working with this long over-looked patient population.

#### C4

#### Tranon Ballroom

#### What to do about QT: Assessing and Reducing Cardiac Risk in the OTP

*Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA*  
*Mori J. Krantz, MD, University of Colorado, Denver, CO*  
*Barry Stimmel, MD, Mt. Sinai School of Medicine, New York, NY*  
*Andrew Byrne, MD, Dependency Medicine, Redfern, New South Wales, Australia*

Methadone is one of many medications that can cause Torsades, a rare cardiac arrhythmia. One in five maintenance patients might be at risk, and two percent are at high risk of this serious cardiac complication. This workshop presents the draft of the findings. Solicitation of comments from the audience will be part of CSAT's Field Review process.

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

## CONFERENCE SESSIONS Tuesday, April 28, 2009

- |  |   |
|--|---|
| <p><b>C5</b> <i>Mercury Ballroom</i></p> <p><b>Outcomes Research: Getting Results that Mean Something</b></p> <p><i>Erin Stevenson, MSW, University of Kentucky CDAR, Lexington, KY</i></p> <p><i>Hilary Jacobs, MSW, MA, Department of Public Health Bureau of Substance Abuse Services, Boston, MA</i></p> <p><i>Frederick Pottle, MPA, CRC Health Group Recovery Division, Carlsbad, CA</i></p> <p>This panel offers different perspectives on outcomes data collection and dissemination for opioid replacement treatment populations. Kentucky's Opiate Replacement Treatment Outcome Study, Massachusetts' Methadone Treatment Quality Assurance System, and CRC Health Group's outpatient clinic network will help answer: How to cost-effectively collect patient level data and get results? How to respond to NOMS and other State, local and Federal data requests? How to translate outcomes into usable products for clinicians, treatment centers and policy-makers?</p> <p><b>Sponsored by Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.</b></p> | <p><b>D2</b> <i>Nassau Suite</i></p> <p><b>Developing &amp; Integrating Peer Mentoring Services</b></p> <p><i>Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT</i></p> <p><i>Kurt Kemmling, CT Chapter National Alliance Methadone Advocates; CT Chapter National Alliance Methadone Advocates, Norwalk, CT</i></p> <p>This workshop will focus on the development, implementation, and integration of peer mentoring services within a methadone treatment program. Potential benefits relating to patient outcomes and staff utilization management will be discussed. The presenters will focus on providing information the workshop participants will need to replicate all or part of the initiative at their own programs. One key area of focus will be the development and implementation of a training curriculum for the peer mentors.</p> |
|--|---|
- 
- |  |   |
|--|---|
| <p><b>1:30PM – 3:00PM</b> <i>Workshop Sessions</i></p> <p><b>D1</b> <i>Mercury Ballroom</i></p> <p><b>Integrating Treatment for Co-Occurring Disorders</b></p> <p><i>Joan E. Zweben, PhD, East Bay Community Recovery Project; Oakland, CA; University of California, San Francisco, CA</i></p> <p>This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the opioid treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate the patients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.</p> <p><i>*Note Basic Track</i></p> | <p><b>D3</b> <i>Beekman Parlor &amp; Sutton North</i></p> <p><b>Genetics and Addiction: A Current and Future Perspective</b></p> <p><i>Mary Jeanne Kreek, MD, The Rockefeller University Hospital, New York, NY</i></p> <p><i>Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment, San Francisco, CA</i></p> <p><i>Louise Haynes, MSW, Medical University of South Carolina, Columbia, SC</i></p> <p>Epidemiologic research has shown that the relative risk of developing an addiction to a substance, following self-exposure, ranges from 30 – 60 percent. Over the past decade significant advances in molecular genetics have identified a variety of variants of specific genes some of which are directly related to processes known to be involved in addiction while others, which are less well understood, offer future discovery. Staff and patients of community opioid treatment programs can and will be involved in the future development of genetic research, this will lead to a better understanding of addiction and thus to more specific treatment approaches which will produce improved treatment outcomes. This session will describe some of the current and future genetics research on opioid addiction and its implications for the treatment community.</p> |
|--|---|

The International Luncheon on Tuesday, April 28, 2009 is supported through grants from Covidien-Mallinckrodt, David Szerlip & Associates, Inc. and Colonial Management, LP.

The Award Pre-Banquet Reception on Tuesday, April 28, 2009 is supported in part through a grant from Smart Software Solutions.



## CONFERENCE SESSIONS Tuesday, April 28, 2009

### D4

### Sutton Center & South

#### Evaluating Multiple Buprenorphine Treatment Approaches and Integration into an IOP

Robert M. Freeman, BS, The APT Foundation, New Haven, CT  
 Lynn M. Madden, MPA, The APT Foundation, New Haven, CT  
 Sam A. Ball, PhD, The APT Foundation; Yale University School of Medicine, New Haven, CT

The APT Foundation, located in New Haven, CT maintains an integrated system of buprenorphine treatment and maintenance services by offering three distinct levels of care including Physician-based practice; Physician-based practice in a traditional outpatient setting; and buprenorphine Maintenance integrated into an OTP. Our evaluation of each program consists of data obtained from the self-administered Basis-24; baseline admission data; patient retention; service level data; and finally patient urinalysis data. Through analysis of patient response in each setting, a system of matching patients to service level as well as the development of a Buprenorphine continuum of care will be discussed.

### D5

### Trionon Ballroom

#### Removing Systems Barriers to Implement Evidence-Based Practices

Kim Johnson, PhD, NIATx- University of Wisconsin Madison, Madison, WI

Victor Capoccia, PhD, NIATx and Open Society, Madison, WI  
 Thomas McLellan, PhD, Treatment Research Institute, Philadelphia, PA

In 2006 the Robert Wood Johnson Foundation initiated the Advancing Recovery program intended to promote adoption of five evidence-based practices in the addiction treatment (wrap around services, continuing care, medication assisted treatment, screening and brief intervention, and psychosocial interventions). This workshop will describe that program, present case examples from four states of how the system changes implementation and what effect they had. A discussion of the program's implications for implementing evidence-based practices will also be included.

## AWARDS PROGRAM

Tuesday, April 28, 2009 7:00PM – 9:30PM **Grand Ballroom**

### Introduction to the Awards Program

Please join us for the centerpiece of our Conference, a moving tribute to those individuals who have been nominated and selected by their peers for extraordinary service in the opioid treatment community. These successful Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983. AATOD has been responsible for bestowing this honor since the first Regional Conference of 1984 in New York.

### The Nyswander/Dole “Marie” Awards will be presented by Anita Townley



Anita Townley was one of the first women admitted to methadone maintenance treatment in the early days of the program. Anita worked at Rockefeller University with Drs. Dole and Nyswander. Anita worked as secretary and assistant to Dr. Marie Nyswander for twenty years. But even more than that, Anita was their close friend; she was a colleague and confidant to Dr. Nyswander and to Dr. Dole. She was part of their extended methadone maintenance family, their social and family life. Anita remained close to Dr. Dole until his recent death. Being at the center of the development and expansion of methadone throughout the US and the world, Anita was able to meet so many of the personalities and early Nyswander/Dole awardees. As a successful patient, methadone treatment made it possible for Anita to work, raise a family and allowed her to travel extensively throughout the world. Anita is now retired, has a son, Bob Townley, who is the CEO of a large youth center in Tribeca and has two wonderful grandchildren.

# AWARDS PROGRAM

Tuesday, April 28, 2009 7:00PM – 9:30PM **Grand Ballroom**

**The 2009 American Association for the Treatment of Opioid Dependence National Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award:**

## **Robert K. Brooner, PhD**

## **Maryland**



Dr. Brooner has tirelessly and successfully served the medication-assisted treatment community in Maryland and elsewhere for more than 20 years. Some of the work that captured the committee's enthusiasm includes: 1) the creation of an adaptive treatment approach for opioid dependence that rapidly adjusts the scope and intensity of services to sustain good clinical response from patients. The Joint Commission honored this work by naming him a 2007 winner of the Ernest Amory Codman Award for innovative treatments that improve quality-of-care and patient safety, and identified the treatment as a "gold standard" for medication assisted programs in the 21st century; 2) his development of a citywide treatment initiative that makes specialized services readily available to poor treatment responders in publicly-supported treatment programs in Baltimore that use methadone; and 3) despite considerable demands on his time, Robert continues to provide clinical care to patients and makes himself readily available as an advisor and mentor to many people and programs.

## **Peter Coleman, MS**

## **New York**



Throughout his career, Peter has been an advocate for moving the opioid treatment system in New York State towards a more patient-centered, evidenced-based approach. Peter has advocated for the provision of comprehensive and co-located services consistent with the chronic disease model of care. In the best traditions of Marie Nyswander and Vincent Dole, Peter believes in listening to patients and insists that our treatment approach must always be respectful of patients' rights, human dignity, and self-determination. Peter has worked towards these goals in his former position at Staten Island University Hospital as well as in the many opioid treatment clinics operated by the New York City Health and Hospitals Corporation. Peter is a leader in our field in New York. He generously shares his time, expertise, and wisdom with others through his work on the COMPA Board and the New York State Governor's Advisory Committee for Alcoholism and Substance Abuse Treatment. Most recently Peter has been an active member of the OASAS Methadone Transformation Advisory Workgroup (MTAG) which seeks to mainstream medication assisted treatment throughout the large addiction treatment system in New York. Peter's principled yet practical voice has been a major force in helping to develop a better OTP treatment system in our state.

## **Kim Comstock, MEd**

## **Texas**



Kim Comstock M.Ed., LPC, a NTP sponsor since 1997, focuses primarily on community education, patient advocacy and empowerment, harm reduction and progressive program implementation. Her efforts include teaching methadone awareness (St. Edwards University and Institute for Chemical Dependency Studies), co-founding Texas Opioid Treatment Alliance, authoring articles advocating MAT for Recovery Today Newspaper, facilitating Texas CPS policy changes to support OTP patients and creating the first PAG (patient advocacy group) in Texas. Kim's programs train interns from local schools and universities. She donates thousands of dollars per year to the clinic's PAG to help patients with fees/financial hardships. She welcomes needle exchange to operate at the clinics. Her programs offer free acupuncture, yoga, a space for MA groups and financial incentives encouraging patients and their families to participate in services. Kim has always placed the interests of her patients as primary in all of her work.

## **Mercedes Lovrecic, MD**

## **Slovenia**



Mercedes Lovrecic MD, MSc – Slovenia (EU) has been a lecturer and practicing clinician in a methadone clinic in Slovenia since 1996. In 2002, with the support of European colleagues she co-founded the first outpatient clinic in Izola, Slovenia for the treatment of addiction and psychiatric comorbidity. In 2002, she received the "Chimera Award" in Oslo for her contribution to the development of effective opioid treatment in Europe. She also works at the National Institute of Public Health for the Republic of Slovenia and has served as a member of the Steering Group for the European Union Action Plan on Drugs. Mercedes is widely published and has frequently presented at EUROPAD and AATOD conferences.

## **Judith Martin, MD**

## **California**



In her 22 years in the addiction treatment field, Dr. Martin has assumed significant leadership roles in providing top quality treatment in a supportive and respectful manner. She is active as a physician working with patients, a teacher, a member of numerous expert committees, chair of important committees, and currently, President of the California Society of Addiction Medicine. Dr. Martin is appreciated for her warmth, intelligence, and graceful leadership style. She is highly knowledgeable, and able to communicate with a wide range of people in a manner that promotes finding common ground. Beginning counselors are enthusiastic about her ability to talk from their perspective, putting medical issues in understandable form. Advanced professionals appreciate her knowledge of the research literature and ability to describe complex issues succinctly. These qualities are evident in her work on many expert work groups, her participation in research, and her publications.



# AWARDS PROGRAM

Tuesday, April 28, 2009 7:00PM – 9:30PM *Grand Ballroom*

## **Gloria J. Mouzon, MD**

## **Illinois**



Through her work as a practitioner at several facilities and on statewide committees over the past 25 years, Dr. Mouzon has made meaningful and consistent contributions that have had significant impact on opioid treatment in Illinois. Due to the high quality of her work and her commitment to patients, Dr. Mouzon has earned the respect of the State Methadone Authority and colleagues throughout Illinois. Patients, regulating authorities, and program staff all rank Dr. Mouzon as an outstanding physician. Dr. Mouzon is highly skilled, demonstrating sound clinical judgment in working with patients with diverse needs. Her warm and open style helps to foster teamwork between nurses, counselors and patients. Dr. Mouzon has an amazing spirit. She approaches her work with honesty and integrity, and holds a deep respect for patients and their right to self-determination. As a physician, Dr. Mouzon has raised the bar for patient care.

## **Raymond M. Pomm, MD**

## **Florida**



Dr. Pomm has worked in addiction treatment over 20 years and holds medical licenses in both Florida and Virginia. He is the Medical Director for River Region Human Services in Jacksonville, Florida. He is also the Medical Director for the Professionals Resource Network/Impaired Practitioners Program of Florida. He developed the first dual diagnosis program for methadone patients with serious psychiatric disorders in 1994 and has continued to set the standard for dual diagnosis care for this population. Dr. Pomm has also worked tirelessly with Family Practice physicians to enhance their understanding and treatment of substance use disorders, but particularly to the issues related to opiate addiction. He has championed the needs of impaired healthcare professionals in order to support their recovery and return to the workforce, including professionals on methadone and/or Suboxone. Dr. Pomm represents opiate addiction treatment services on several committees and workgroups at the state level.

## **Deborah Powers, BS**

## **Wisconsin**



Ms. Powers is a tireless State Methadone Authority. Frequently she is at the office on weekends and available on her scheduled days off to resolve patient care issues. She is always willing to share her knowledge of pharmacology during patient staffings, especially drug interactions for pregnant women and the fetal impact. She has even provided clinical consultation to the Chief Medical Officers within the Department on the issue of drug interactions. Medication-assisted treatment remains one of the most stigmatized modalities in the treatment for substance use disorders and controversy surrounds it to this day. Deb has done a tremendous job to reduce the stigma and increase awareness around methadone maintenance. She has reminded all of us that treatment professionals remain leaders in the field of stigma reduction by conveying the understanding of the neuroscience of addiction, treatment effectiveness, and to act in the best interest of our patients for timely coordination of care.

## **Alan Wartenberg, MD**

## **Rhode Island**



Dr. Wartenberg is the former Medical Director of the Addiction Recovery Program at Faulkner Hospital, and recently retired as the Corporate Medical Director of Discovery House Programs. He is the Associate Medical Director for the Providence VA Opioid Treatment Program and on the faculty of Tufts University School of Medicine. He is a fellow of the American Society of Addiction Medicine and the American College of Physicians specializing in medical management of addiction problems, including detoxification, and addiction psychopharmacology focusing on opioid treatment, including methadone and buprenorphine. He is a respected author and teacher in these areas. He has advocated for patients in need of treatment to have easy access and is passionate about providing excellent care to his patients.

## **Friend of the Field Award**

### **Presented by Mark W. Parrino, MPA**



*President American Association for the Treatment of Opioid Dependence, Inc.*

The prestigious Friend of the Field Award was established by the American Association for the Treatment of Opioid Dependence, Inc. Board of Directors. This award recognizes extraordinary contributions to the field of opioid treatment by an individual or institution whose work, although not directly related to opioid treatment, has had a significant impact on our field. The 2009 Friend of the Field Award has been awarded to:

### **A. Thomas McLellan, PhD**



Dr. McLellan, CEO of the Treatment Research Institute, is perhaps best known for his pioneering introduction of the Addiction Severity Index and Treatment Services Review in the 1980s. Dr. McLellan later conceptualized data-driven measurement of treatment effectiveness, performance-based monitoring, and analysis of the nation's substance abuse treatment system. Through his research and extensive knowledge of substance abuse treatment systems, Dr. McLellan has become a persuasive proponent of the view that addiction is a chronically relapsing condition, one that must be continually monitored and managed. Dr. McLellan has published more than 400 articles and chapters on addiction research and serves as Editor-in-Chief of the Journal of Substance Abuse Treatment. He is also an advisor to numerous government and nonprofit scientific organizations, including the Office of National Drug Control Policy, Research and Evaluation; the National Practice Laboratory of the American Psychiatric Association, the Swiss National Science Foundation, the World Health Organization, and the Greek government.

# AWARDS PROGRAM

Tuesday, April 28, 2009 7:00PM – 9:30PM **Grand Ballroom**

## Richard Lane / Robert Holden Patient Advocacy Award

Presented by **Jocelyn Woods, MA & Anthony Scro**



Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation's first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor's Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike. Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of the American Association for the Treatment of Opioid Dependence, succeeding Richard Lane's term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

## Walter Ginter, CMA



Mr. Ginter is the Project Director of NAMA's Medication Assisted Recovery Service (M.A.R.S.) Project. He currently serves as national recovery advocacy and an At Large Director of Faces and Voices of Recovery (FaVoR), as a National Recovery Month Planning Partner, Chair of the Expert Panel creating a Guide to Implement a Recovery Oriented System of Care in OTP's, and on the steering committee of the Digital Access to Medication (DATM) emergency database project. In NYS, he serves on the Methadone Transformation Advisory Group (MTAG) as Chair of the Recovery Committee and on the Commissioners Recovery Implementation Team (RIT). Walter has represented patients on more than 30 state and federal committees and panels and is responsible for creating NAMA's Certified Methadone Advocate Training program. He is an extraordinary advocate who has raised awareness among patients, treatment providers and regulatory authorities. He has had a profound and positive effect on improving patient advocacy throughout the nation.

*The 2009 Awards Banquet is supported through a grant from Covidien-Mallinckrodt.*

## CONFERENCE SESSIONS Wednesday, April 29, 2009

**7:00AM**

**Continental Breakfast**  
Sponsored by VistaPharm, Inc.

**2nd Floor Promenade**

**8:00AM – 9:30AM**

### Workshop Sessions

**E1**

**Mercury Ballroom**

#### Focus on the Therapeutic Relationship

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This "basic track" workshop will focus on the essential fundamental counseling skill of forming and maintaining the therapeutic relationship. The presenter will help the participants assess their current core counseling skill set and provide an overview of the counseling techniques used to form and maintain the therapeutic relationship.

*\*Note Basic Track*

**E2**

**Beekman Parlor & Sutton North**

#### Methadone and Social Responsibility: A Public Education Campaign

Ivette A. Torres, MEd, DHHS/SAMHSA/CSAT, Rockville, MD

Michele L Monroe, BS, DHHS/SAMHSA/CSAT, Rockville, MD

Ellen Frank, DHHS/SAMHSA/CSAT, Silver Spring, MD

The goal of this workshop is to educate participants on the available materials and goals of SAMHSA/CSAT's public education campaign, which aims to inform consumers that methadone is an effective treatment for opioid addiction and pain management, when taken as directed, and to health care professionals and clinics that methadone is known to have a complex pharmacology with life threatening interactions when taken with other medications or not as prescribed.

**Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**



## CONFERENCE SESSIONS Wednesday, April 29, 2009

### E3 Sutton Center & South

#### Housing the Homeless Methadone Patient

*Herman Joseph, PhD, Retired Research Scientist, New York, NY*

*Sam Tsemberis, PhD, Pathways to Housing, New York, NY*

*William Panepinto, MSW, NYS Office of Alcohol & Substance Abuse Services, Albany, NY*

Many homeless methadone patients have a range of co-occurring mental disorders and histories of arrests and incarceration. They face a unique stigma which limits their acceptance into programs and services. Pathways to Housing has targeted a housing-first program for this group and the majority of patients have responded positively to services offered. NYS OASAS, cognizant of the issues facing service provision for homeless methadone patients, has developed plans to address this issue which will be presented during this workshop.

### E4 Trianon Ballroom

#### Methadone Mortality Update

*Jane C. Maxwell, PhD, University of Texas at Austin, Austin, TX*

*Bruce Goldberger, PhD, University of Florida College of Medicine, Gainesville, FL*

*Robert Lubran, MA, Center for Substance Abuse Treatment; Substance Abuse and Mental Health Services Administration, Rockville, MD*

This session will review current data on methadone-associated deaths and the extent such deaths might be related to clinical practices of programs to which, as well as strategies to improve the quality of reporting, including uniform nomenclature, case definitions, and standards for toxicological testing to encourage uniform reporting. It will also discuss the latest actions by authorities to address the problem through improved data collection and training health care professionals in the management of pain and addiction.

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

### E5 Nassau Suite

#### The Matrix Model for Medication-Assisted Treatment

*Michael J. McCann, MA, Matrix Institute on Addictions, Los Angeles, CA*

*Daniel George, MPH, Matrix Institute on Addictions, Los Angeles, CA*

The Matrix Model Intensive Outpatient Treatment has been widely disseminated nationally and internationally. A growing number of providers of medication-assisted treatment have requested similar training and, in order to accommodate this need, the Matrix Institute has developed the Matrix Model Outpatient Program for Medication-assisted Treatment. This workshop will describe the core

elements of the Matrix Model, address the special issues relevant to this patient population, and describe the program for medication-assisted treatment.

**9:45AM – 11:15AM**

### Workshop Sessions

#### F1 Mercury Ballroom

##### One Year Later: Lessons Learned in the Implementation of Maryland's Four Jail-Based OTP's

*Greg Warren, MA, Maryland Department of Public Safety and Correctional Services, Baltimore, MD*

*Akin Ayeni, MD, Correctional Medical Services, Inc., Baltimore, MD*

The workshop will describe the challenges of implementing an OTP within a large and busy city jail, as well as how to forge linkages between institutional and clinical staff and with community OTPs. One year outcome data will be shared and its lessons learned- implications on clinical processes as well as its effect on the public health treatment system in Baltimore City.

*\*Note: Basic Track*

#### F2 Beekman Parlor & Sutton North

##### Expanding and Improving the Health Responses to Drug and Alcohol Addiction: The National Advocacy Campaign

*Paul Samuels, JD, Legal Action Center, New York, NY*

*Gabrielle de la Gueronniere, JD, Legal Action Center, Washington, DC*

This workshop session will focus on an upcoming national campaign to expand and improve the health responses to drug and alcohol addiction, and to eliminate discrimination against people in recovery. This session will highlight the campaign's focus on expanding access to medication-assisted treatment and eliminating policies that discriminate against people with opioid addiction histories. The presentation will include discussion of messaging and outreach strategies, and an update on federal and state policy matters.



## CONFERENCE SESSIONS Wednesday, April 29, 2009

### F3 *Sutton Center & South*

#### **“Leave No Man Behind:” Clinical Considerations for Working with Veterans in Addictions Treatment**

*Carol Davidson, LCSW, Samaritan Village Veterans Program, New York, NY*

Military service is a significant and transformative life experience that influences personal development throughout the life span of our veterans. This workshop will describe essential elements of the clinical culture, core treatment principles, and specialized services for combat-related PTSD that are offered in an addictions treatment program for veterans.

### F4 *Trionon Ballroom*

#### **Methadone Dose Reductions in Response to Benzodiazepine Abuse/Dependence: An Evaluation of a New Clinic Protocol**

*Janet G. Morgan, RN, Addiction Research and Treatment Services, Denver, CO*

*Denise E. Vincioni, MA, Addiction Research and Treatment Services, Aurora, CO*

This presentation will examine the impact of a protocol of reducing methadone dose levels for patients testing positive for unapproved benzodiazepine use or for overt benzodiazepine impairment. Data will be presented on illicit opiate use, retention, and increase in other drug or alcohol use, as well as accidental multi-drug overdoses before and after implementation of policy; the benefits of the policy for safety, against the possible decrease in the efficacy of MAT will be discussed.

### F5 *Nassau Suite*

#### **Methadone Transformation in New York State – Process and Outcomes**

*Frank McCorry, PhD, NYS Office of Alcohol & Substance Abuse Services, New York, NY*

*Henry Bartlett, Committee of Methadone Program Administrators of New York State (COMPA), New York, NY*  
*Belinda Greenfield, MA, NYS Office of Alcohol & Substance Abuse Services, New York, NY*

New York State stakeholders, including opioid treatment providers, coalition and advocacy groups, in conjunction with the state chemical dependency agency, have begun a journey towards transforming the state's opioid treatment

system. The concepts that are driving transformation, the linkages with other inter-/intra-agency workgroups, and fiscal reform efforts impacting these efforts will be discussed. The products and implementation strategies of methadone transformation will be presented from the state, provider and patient perspective.

## CLOSING PLENARY SESSION

**11:30AM – 12:45PM**

*Grand Ballroom*

### **Policy, Programs and People**



*Robert B. Millman, MD, Saul P. Steinberg Distinguished Professor of Psychiatry and Public Health, Weill Medical College, Cornell University and Director of the Drug and Alcohol Abuse Treatment and Research Service at the New York Hospital/ Columbia Presbyterian Medical Center*



*Mathea Falco, Esq., President of Drug Strategies, a non-profit research institute in Washington, D.C. promoting more effective approaches to the nation's drug problems and former Assistant Secretary of State for International Narcotics Matters during the Carter Administration*



*Edward H. Jurith, Acting Director, Office of National Drug Control Policy, Executive Office of the President*

Our Special Closing Plenary will unite the voices and themes of AATOD 2009. Participants will gain an unique understanding of public policy and system change, treatment programs into the future and the importance of our patients and their needs. Mathea Falco and Robert Millman will bring new perspectives, insights and voices that shape change to our conference. Chaired by Dr. Millman, our speakers will provide focus and direction to our public policy agenda, our programs and the treatment we provide. Edward Jurith will discuss the importance of effective treatment programs that are based in solid research and science. As we return to our homes and workplaces, this closing plenary will emphasize our core mission, our patients and those who still need our help.

**Join AATOD Today!**  
**www.aatod.org**



# Welcome to New York City

## The Hospitality Committee is ready to roll out The AATOD Stimulus Package



Start by relaxing at The Spa at Mandarin Oriental walking distance from our Host Hotel, Columbus Circle at 60th street, knock 25% off any hour or more treatment booked Monday through Wednesday by mentioning the TONY special.

Excite your mind with a simple call to 212-833-5414 to reserve FREE tickets to The Sony Wonder Technology Lab, Madison Avenue at 56th street, this four-story; interactive technology and entertainment museum is for all ages.

Indulge your taste buds for lunch or dinner at the New York Thai Grill & Sushi Bar, 54th Street between 5th and 6th Avenues, where sushi and non-sushi eaters alike can enjoy an eclectic menu of Asian delights with something for everyone at the All-U-Can-Eat price of \$25.00. The steamed vegetable dumplings and Mango Chicken are menu favorites.

Of course no New York City trip would be complete without a night of Discounted Entertainment. The newly remodeled TKTS Booth at 47th and Broadway (Duffy Square) offers half price tickets to most of the Broadway and Off Broadway wonders. Ok last year's TONY winner In the Heights and Long running smash Wicked won't be on the boards at TKTS but come by the Hospitality booth and we will let you in on the little known secret to Discounted tickets to these Hot shows.

To learn more about these and other discounts available, feel free to visit the Hospitality Committee booth or speak with the NYC & Company volunteers located in the Registration Area. For those interested in seeing some of New York City's Opioid Treatment Programs first hand, you can sign up to participate in our Clinic Tours on Wednesday.

Once again, Welcome to New York City. We look forward to guiding your personal stimulus package.

*Cost-consciously submitted by Haynes, the 2009  
AATOD Hospitality Chair.*

How to Enjoy New York City For Less





## CONFERENCE NOTES

- Smoking is prohibited at all conference events.
- Your conference badge is your admission to all events and educational sessions. Please be sure to wear your badge to all conference functions.
- Participation in this conference assumes knowledge and authorization of audio and / or video recordings of portions of this conference.
- Part of the proceeds of the sleeping room rates will be used to defray conference expenses.
- Please take the time to complete all evaluation forms. Your feedback is extremely important to the presenters and AATOD.

### AUDIO TAPING INFORMATION

#### *Don't Miss A Single Important Word!*

As a special service to attendees, the presentations will be available on Audio CD.

With scheduling conflicts and concurrent sessions, Job Conference will make it possible to attend every important session via audio CD, using advanced techniques assuring the highest quality recordings.

High-speed duplication equipment eliminates long delays, allowing you to hear the important information shortly after each session has concluded. The CDs provide an excellent recap and a valuable training tool to those who could not attend.

Look for the **Job Conference** order desk located on the 2nd Floor Promenade area and take your information home with you, or place an order through the mail after the conference. Please refer to your registration packet for a complete listing of available sessions.

#### **Job Conference**

**Phone: 1-888-609-TAPE**

**Email: Job\_CRS@att.net**

### A SPECIAL NOTE FOR THE DISABLED



The American Association for the Treatment of Opioid Dependence, Inc. has taken steps required to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services, as outlined in the Americans with Disabilities Act.

### CONTINUING MEDICAL EDUCATION (CME) / CONTINUING EDUCATION HOURS (CEHs)

The 2009 AATOD National Conference will award Continuing Medical Education (CME) and Continuing Education Hours (CEHs). Please see the back cover for specific information.

To apply for CMEs / CEHs, conference attendees must pay the associated fee, either in advance or at the on-site conference registration desk. **Attendance at conference events will be verified electronically.** Each attendee seeking CMEs / CEHs will have a bar code attached to his/her conference badge. **At the end of EACH approved session, attendees must have the bar codes on their badges "scanned" by room monitors in order to record CME / CEH.** These monitors will have electronic equipment that will automatically record each individual's attendance in a database. The database will track and tabulate each attendee's CMEs / CEHs. After the conference, certificates documenting attendance and the number of CMEs / CEHs earned will be electronically generated and mailed to all eligible attendees.

Attendees participating in **ALL** six Basic Track workshops will receive an additional certificate documenting their participation in this special training series.


Questions about CMEs / CEHs can be answered by staff at the Conference CME / CEH Desk located in the registration area.

**NEW YORK CITY INFORMATION IS LOCATED AT THE HOSPITALITY BOOTH IN THE REGISTRATION AREA.**

## HOTEL FLOOR PLAN

## HILTON NEW YORK

## 2ND FLOOR







## HOTEL FLOOR PLAN

### HILTON NEW YORK

#### 3RD FLOOR



#### 4TH FLOOR



## EXHIBITOR DIRECTORY

The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation.

### Addiction Professional

149 5th Avenue

New York, NY 10010

Ph/Fax: 212-812-4674; 212-228-1308

rbeneventi@vendomegrp.com

Addiction Professional is the addiction field's essential guide to what is working in treatment and prevention and how clinicians can use this knowledge to achieve excellence in services.

### Browse Table

### Addiction Technology Transfer Center-National Office

5100 Rockhill Road

Kansas City, MO 64110

Ph/Fax: 816-235-6888; 816-235-6580

christyc@umkc.edu • www.ATTCnetwork.org

As a nationwide, multidisciplinary resource for professionals in the addictions treatment and recovery services field, the ATTC Network serves to: Raise awareness of evidence-based and promising treatment and recovery practices, Build skills to prepare the workforce to deliver state-of-the-art addictions treatment and recovery services, and Change practice by incorporating these new skills into everyday use for the purpose of improving addictions treatment and recovery outcomes.

### Booth #325

### Addiction Treatment Providers Insurance Program

555 North Lane, Suite 6060

Conshohocken, PA 19428

Ph/Fax: 610-941-9877; 610-941-9889

rjwillets@nsminc.com • www.addictiontreatmentproviders.com

The Addiction Treatment Providers Insurance Program is an exclusive program for the Addiction Treatment and Behavioral Health Treatment Industry. ATP offers coverage to meet the unique needs of all addiction & mental health treatment facilities and services a wide range of residential and outpatient treatment facilities and psychiatric & mental health clinics.

### Booth #227

### AIT Laboratories

2265 Executive Drive

Indianapolis, IN 46241

Ph/Fax: 800-875-3894; 317-243-2789

ClientServices@AITLabs.com • www.AITLabs.com

AIT Laboratories offers state-of-the-art analyses for pain management and clinical clients nationwide. Based in Indianapolis, AIT's services include access to on-site board-certified toxicologists, instant-cup testing to identify drug misuse in new patients, a comprehensive urinalysis to monitor compliance, and immediate access to results via online reporting at www.AITLabs.com.

### Booth #223

### American Association for the

### Treatment of Opioid Dependence, Inc. (AATOD)

225 Varick Street, 4th floor

New York, NY 10014

Ph/Fax: 212-566-5555; 212-366-4647

info@aatod.org • www.aatod.org

The American Association for the Treatment of Opioid Dependence, Inc. (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive opioid treatment services throughout the United States. AATOD works with federal agencies, state substance abuse authorities and agencies within the criminal justice system concerning opioid treatment policy in addition to coordinating activities with advocacy groups and treatment providers in all regions of the country. AATOD continues to work on behalf of all its members by expanding access to quality addiction treatment services.

### Booth #110

### Ammon Analytical Laboratory, LLC

1622 South Wood Avenue

Linden, NJ 07036

Ph/Fax: 908-862-4404; 908-862-0605

nreyes@ammontox.com • www.ammontox.com

Ammon Analytical is a specialty state-of-the-art toxicology laboratory. Our niche market is dedicated to providing excellent service to those clinics seeking treatment for the opioid dependent community. Our facilities include sophisticated instruments and computer management systems that empower us with an efficient means to handle all of our client needs.

### Booth #212

### Anthony C. Baker Architects & Planners, P.C.

53 South Main Street Freeport

New York, NY 11520

Ph/Fax: 212-947-5818; 516-632-9748

acb@acb-architects.com • www.acb-architects.com

ACB Architects and Planners P.C. are established Architectural Design professionals in The Health Care field and specialize in services for OPIOID dependent clientele and the associations who provide its treatment. Built work includes clients like: Einstein College of Medicine, St. Vincent's / Catholic Medical Centers, Beth Israel, & St. Mary's Hospital.

### Booth 128

### ASI-MV Connect

320 Needham Street, Suite 100

Newton, MA 02464

Ph/Fax: 617-332-6028; 617-332-1820

smehringer@inflexxion.com • www.asi-mvconnect.com

The Addiction Severity Index-Multimedia Version® Connect system is a powerful web-enabled version of ASI-MV that moves substance abuse assessment, treatment planning and data management to new heights. The system includes the client self-administered interview, clinical reports, and the ASI-MV Connect Data Center to simplify data gathering and analysis.

### Booth #316

### Bendiner & Schlesinger

140 58th Street, Suite 8D

Brooklyn, NY 11220

Ph/Fax: 212-353-5111; 212-598-0907

info@bendinerlab.com • www.bendinerlab.com

Bendiner & Schlesinger, Inc., a full-service laboratory, has more than 40 years experience in meeting the testing needs of treatment programs for opioid dependence throughout the U.S. Bendiner & Schlesinger, Inc. offers laboratory-based urine and oral-fluid drug screening, including complete differentiation and quantitation of positive screens of either specimen type.

### Booth #112

### Beth Israel Medical Center

Chemical Dependency Programs

MMTP and Stuyvesant Square

160 Water Street, 24th Floor

New York, NY 10038

Ph: 212-420-2230

smquirk@chnpnet.org • www.BethIsraelNY.org

For more than 40 years, Beth Israel Medical Center has operated the largest non profit MMTP in the U.S. with 17 clinics throughout Manhattan and Brooklyn. Methadone has proven an invaluable tool for effective treatment and rehabilitation of opioid-addicted individuals. Our team works together to help patients eliminate opioid addiction and become self reliant.

### Booth #314

### Brown Consulting, Ltd

121 N. Erie Street

Toledo, OH 43604

Ph/Fax: 800-495-6786; 419-241-8689

rwilhigh@danbrownconsulting.com • www.danbrownconsulting.com

Since 1987, Brown Consulting, Ltd. has provided a full range of Research, Management Regulatory Compliance and Consulting Services for more than four hundred (400) organizations across thirty-eight (38) states. Today, Brown Consulting, Ltd. has established national recognition as a leader among Behavioral Services Consulting Organizations. Contact us at 800-495-6786.

### Browse Table



# EXHIBITOR DIRECTORY

## C & C Containers, LLC

2607 Ledo Road  
Albany, GA 31707

Ph/Fax: 229-869-6071; 229-903-0025

astone@ccccontainers.net • www.ccccontainers.net

C&C Containers is your medication bottle solutions company; specializing in providing affordable take-home bottles and child proof caps to Medication Assisted Treatment programs.

**Booth #231**

## CARF International

4891 East Grant Road

Tucson, AZ 85712

Ph/Fax: 520-325-1044; 520-318-1129

bharrison@carf.org • www.carf.org

Founded in 1966 as the Commission on Accreditation of Rehabilitation Facilities, CARF International is an independent, nonprofit, accreditor of human service providers. CARF serves as a catalyst for improving the quality of life of the persons served by CARF-accredited organizations and the programs and services they provide. Please come by our booth or visit us online at www.carf.org.

**Booth #221**

## Clinical Science Laboratory, Inc.

51 Francis Avenue

Mansfield, MA 02048

Ph/Fax: 800-255-6106; 508-339-3540

don@clinicalsciencelab.com • www.clinicalsciencelab.com

Clinical Science Laboratory is the premier toxicology laboratory for the testing needs of opioid addiction treatment facilities. We tailor drug screens, both urine and oral fluid, to meet your testing requirements, and do all clinical blood testing in-house. Our trademark is "Personalized Service With Professional Commitment Since 1974."

**Booth #321**

## Council on Accreditation

120 Wall Street

New York, NY 10005

Ph/Fax: 212-797-3000; 212-797-1428

dwood@coanet.org • www.coanet.org

Founded in 1977, the Council on Accreditation (COA) is an independent not-for-profit accreditor of the full continuum of community-based behavioral health care and social service organizations in the United States and Canada, and is one of the three leading accreditors of such service providers. Originally known as an accrediting body for family and children's agencies, COA currently accredits 44 different service areas and over 70 types of programs. Over 1800 organizations -- voluntary, public and proprietary, local and statewide, large and small have either successfully achieved COA accreditation or are currently engaged in the process.

**Booth #213**

## Covidien-Mallinckrodt

675 McDonnell Blvd.

St. Louis, MO 63042

Ph/Fax: 800-325-8888; 314-654-7128

Robert.lesnak@covidien.com • www.mallinckrodt.com

Covidien-Mallinckrodt manufactures a complete line of Methadone products including Powders, Oral Concentrates (cherry flavored and sugar-free), and Dispersible tablets, unflavored and orange flavored. Mallinckrodt continues to support the field of addiction treatment with the AT Forum and ATF Website, ForumFax, patient education brochures and a series of training modules for clinicians.

**Booth #216**

## Emerging Solutions in Pain

101 Washington Street

Morrisville, PA 19067

Ph/Fax: 215-337-0956; 215-337-0959

www.emergingsolutionsinpain.com

Emerging Solutions in Pain is a non-branded disease awareness initiative focused on chronic pain management and the issues of abuse, misuse, and addiction of opioids. Our diverse array of resources were developed to assist clinicians in overcoming the challenges they face when treating patients with pain. Today's source for tomorrow's pain management!

**Booth #328**

## Friends Medical Laboratory

5820 Southwestern Blvd.

Baltimore, MD 21227

Ph/Fax: 410-247-4417; 410-247-4426

artdstgmn@aol.com • www.Friendslab.com

Friends Medical Laboratory (FML) is a toxicology laboratory that has been performing drug testing since 1963. In 1968 FML began testing for methadone programs. FML offers a wide range of testing for drugs of abuse. They can test urine and oral fluid samples as well as offer confirmations of any pre-screening instant kits. FML has recently begun offering point of care or instant drug testing kits for both urine and oral fluids. Moreover, FML has begun offering testing to Pain Management Physicians. For more information please go to www.Friendslab.com.

**Booth #232**

## GlaxoSmithKline

Three Franklin Plaza, 1600 Vine Street

Philadelphia, PA 19101

Ph/Fax: 800-366-8900

www.gsk.com

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Please visit our exhibit to learn more about our products.

**Booth #126**

## Graham-Massey Analytical Labs, Inc.

60 Todd Road

Shelton, CT 06484

Ph/Fax: 800-288-6365; 203-225-2744

kkilbourn@graham-massey.com • www.grahammassey.com

Graham-Massey Analytical Labs is a full-service medical laboratory dedicated to providing a wide range of quality services -- from substance abuse testing to clinical laboratory testing.

**Booth #130**

## MP Biomedicals

3 Hutton Centre Drive, Suite 100

Santa Ana, CA 92707

Ph/Fax: 888-842-8378; 949-859-5010

David.Katrowski@mpbio.com • www.mpbio.com

MP Biomedicals is a leading world-wide manufacturer of immunodiagnostic products. Our qualitative one-step rapid devices are available in different formats that are highly sensitive with ease of use. We also supply saliva tests for the detection of alcohol.

**Booth #326**

## Millin Associates LLC

521 Chestnut Street

Cedarhurst, NY 11516

Ph/Fax: 516-374-4530; 516-374-8613

jparker@millinmedical.com • www.millinmedical.com

Millin Associates LLC is the Healthcare Industry's specialist for converting unpaid Medicaid, Medicaid Managed Care, Medicare Health Insurance and third party claims into paid claims. Equipped with a HIPAA compliant state-of-the-art claims processing system, we provide substantially error-free billing and increased reimbursement for our clients. All fees are contingency based.

**Booth 332**

## National Institute on Drug Abuse (NIDA)

6001 Executive Blvd., Suite 5213

Bethesda, MD 20892

Ph/Fax: 301-594-6142; 301-443-7397

jnolan1@nida.nih.gov • www.drugabuse.gov

NIDA is a Federal agency charged with supporting research on the causes, prevention, and treatment of all aspects of drug abuse including AIDS. Results of NIDA-funded research help solve the medical, social, and public health problems of drug abuse and addiction. Publications and research opportunities will be made available.

**Booth #210**

## Natalytics

102 Trade Street

Greer, SC 29651

Ph/Fax: 864-416-0153; 864-416-0157

kessex@natalytics.com • www.methasoft.com

Methasoft® is an industry leading product for the management and provision of care in the opioid treatment arena. Methasoft® is a fully integrated system from patient check-in kiosk to billing. Methasoft® is a fully automated, flexible software that utilizes leading technologies including Microsoft.NET Framework and SQL Server 2005.

**Booth #209**

# EXHIBITOR DIRECTORY

## Netsmart Technologies

3500 Sunrise Highway, Suite D122

Great River, NY 11739

Ph: 800-421-7503

info@ntst.com • www.ntst.com

Netsmart Technologies is the trusted partner for health and human services' largest connected community of providers and payers. Netsmart Methadone software solutions provide a range of options for both stand-alone methadone clinics and organizations with an integrated methadone treatment program. More than 500 clinics nationwide use Netsmart's solutions to enhance operational efficiencies, which ultimately lead to improved methadone treatment.

**Booth #120**

## New York State Office of Alcoholism and Substance Abuse Services (OASAS)

1450 Western Avenue

Albany, NY 12203

Ph/Fax: 518-473-3460; 518-485-6014

communications@oasas.state.ny.us • www.oasas.state.ny.us

The New York State Office of Alcoholism and Substance Abuse Services (OASAS) oversees one of the nation's largest addiction services systems, including 1,550 prevention and treatment providers serving 110,000 New Yorkers on any given day. For information on prevention, treatment, recovery in New York State, visit [www.oasas.state.ny.us](http://www.oasas.state.ny.us) or call 1-877-8-HOPENY.

**Booth #319**

## NIATx Booth #315

1513 University Avenue, Room 4121

Madison, WI 53726

Ph/Fax: 608-265-0063; 608-890-1438

info@niatx.net • www.niatx.net

NIATx is a pioneering improvement collaborative that works with behavioral health organizations across the country. We teach organizations to use a simple process improvement model developed at the University of Wisconsin-Madison. NIATx helps behavioral health payers and providers improve access to and retention in treatment.

**Booth #225**

## NOVX Systems Inc.

185 Renfrew Drive

Markham, ON L3R 6G3 Canada

Ph/Fax: 877-879-6689; 905-474-1023

novxinfo@novxsystems.com • www.novxsystems.com

NOVX Systems provides a complete and powerful drug screening solution that allows an informed decision to be made on-site. The FDA cleared iMDx Analyzer quickly provides semi-quantitative results that are automatically uploaded into its PatientVu EMR. PatientVu manages results, scheduling, billing, reporting and much more! Start screening smarter and reporting faster today!

## O.Berk of New England / Kols Containers, Inc

220 Frontage Road

West Haven, CT 06516

Ph/Fax: 203-932-8000; 203-934-7172

bkursawe@oberk.com • www.oberk.com

O.Berk and Kols are full service packaging distributors. We supply "take-home" bottles and child-resistant caps, as well as tamper-evident seals and dispensing cups. We have warehouses in West Haven, CT and Baltimore, MD with large inventories of bottles and caps to serve your packaging needs.

**Booth #215**

## OraSure Technologies Inc.

220 East First Street

Bethlehem, PA 18015

Ph/Fax: 610-882-1820; 610-814-3405

LRomero@OraSure.com • www.orasure.com

OraSure Technologies, Inc., the pioneer of oral fluid drug testing, manufactures and markets the Intercept® Oral Fluid Drug Test System collection device and diagnostic immunoassays. Intercept combines the ease, efficiency and cost savings of oral fluid collection with significantly increased sample integrity and the accuracy of lab-reliable, proven results.

**Booth #108**

## Patient Support and Community Education Project

P.O. Box 26377

Washington, DC 20001

staff@atwatchdog.org

www.atwatchdog.org

PSCEP is a coalition of national medication assisted treatment patient education and support groups. The member organizations include AFIRM - [www.afirm.org](http://www.afirm.org); Advocates for Recovery through Medicine - [www.methadonetoday.org](http://www.methadonetoday.org); ATWatchdog - [www.atwatchdog.org](http://www.atwatchdog.org); Methadone Support - [www.methadonesupport.org](http://www.methadonesupport.org); National Alliance of Methadone Advocates - [www.methadone.org](http://www.methadone.org) and the Opiate Dependence Resource Center, [www.methadone.net](http://www.methadone.net) <<http://www.methadone.net>> .

**Booth #233**

## Reckitt Benckiser Pharmaceuticals, Inc.

10710 Midlothian Turnpike, Suite 430

Richmond, VA 23235

Ph/Fax: 732-919-1234; 732-280-1350

Reckitt Benckiser Pharmaceuticals is at the forefront providing educational resources and treatment options to physicians and patients dealing with the chronic relapsing disease of opioid dependence. Please visit their exhibit where Reckitt Benckiser Managed Care Account Managers will be available to provide scientific information and answer your questions.

**Booth #134**

## Redwood Toxicology Laboratory, Inc

3650 Westwind Blvd

Santa Rosa, CA 95403

Ph/Fax: 707-577-7959; 707-577-8102

sbertulucci@redwoodtoxicology.com • [www.redwoodtoxicology.com](http://www.redwoodtoxicology.com)

At Redwood Toxicology Laboratory, Inc. (RTL), one of the nation's premier forensic drug testing facilities, we offer you comprehensive, cost effective drug and alcohol testing options. We deliver the certainty of science, the dependability of proven drug screening processes and the assurance of legally defensible results. Our laboratory services include urine drug testing, oral fluid drug testing, prescription drug testing, EtG/EtS alcohol testing, steroid testing and more.

**Booth #309**

## Roxane Laboratories, Inc.

1809 Wilson Road

Columbus, OH 43228

Ph/Fax: 888-831-2183; 614-308-3576

www.roxane.com

Headquartered in Columbus, Ohio, Roxane Laboratories is a recognized leader in researching, manufacturing, and packaging nearly 300 medications including oral liquids, tablets, capsules and cytotoxic pharmaceutical products. Most recently, Roxane acquired the rights to the Cebert Pharmaceuticals line of Methadone Diskets®, Oral Concentrate and Power effective January 30, 2009.

**Booth #211**

## SAMMS

510 S. Wesley

Oak Park, IL 60304

Ph/Fax: 877-717-SAMM; 800-789-0954

samms@priceconsultinginc.net • [www.sammsystem.com](http://www.sammsystem.com)

SAMMS is a fully customizable Electronic Clinic Management and Medication Dispensing System. We provide 24/7/365 live answered, quality support by Substance Abuse Technology Professionals. SAMMS is the most cost effective dispensing solution on the Market and quotes can be tailored to meet any budget.

**Booth #333**

## San Diego Reference Laboratory

6122 Nancy Ridge Drive

San Diego, CA 92121

Ph/Fax: 800-677-7995; 858-677-7998

www.sdrl.com

San Diego Reference Laboratory is a client-focused toxicology laboratory, specializing in drug of abuse testing. We offer specifically designed urine/saliva laboratory panels and cost effective onsite products to accommodate your program's needs. SDRL offers clients Quality Service, Accurate Test Results, Accessibility to Technical information, and Rapid Turn Around Time.

**Booth #208**



# EXHIBITOR DIRECTORY

### Siemens Healthcare Diagnostics

1717 Deerfield Road  
Deerfield, IL 60015  
Ph: 847-267-5300

Kaiyane.bynoe@siemens.com • www.siemens.com/diagnostics

When the stakes are too high to be wrong; turn to the experts in Drug Testing at Siemens Healthcare Diagnostics. Syva EMIT®, is the world's leading drug monitoring methodology, and Siemens offers a comprehensive portfolio of products for drugs of abuse, specimen validity, point of care testing, and data management.

### Smart Software Solutions

66 Pavilion Avenue  
Providence, RI 02905

Ph/Fax: 401-780-2300; 401-780-2350

SMART Software Solutions is a premiere provider of computer software for substance abuse treatment. The Smart System is used by over 100 providers throughout the United States and Europe. With 22 of our own facilities, SMART was the distinction of being the only software provider that actually uses its own software.

### STERLING Reference Laboratories

2617 East L Street, Suite A  
Tacoma, WA 98421-2201

Ph/Fax: 800-442-0438; 253-552-1549

sales@regtox.com • www.sterlingreflabs.com

STERLING Reference Laboratories is an established methadone – experienced toxicology laboratory testing for drugs of abuse, delivering responsive service and affordable prices. SRL is unique, offering customized drug testing services to meet each customers needs and live access to our Scientists regarding drug testing. Call 1-800-442-0438 to learn more!

### Substance Abuse and Mental Health Services Administration

11300 Rockville Pike  
Rockville, MD 20852

Ph/Fax: 204-221-4058; 301-945-4296

request@samhsaexhibits.org • www.samhsa.gov

SAMHSA is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity and effectiveness of the nation's substance abuse and prevention, additions treatment, and mental health services delivery system.

### The Joint Commission

One Renaissance Blvd  
Oakbrook Terrace, IL 60181

Ph/Fax: 630-792-5866; 630-792-4866

echoi@jointcommission.org • www.jointcommission.org/BHC

Accreditation from The Joint Commission helps create a standards-based culture of excellence, assisting you in providing the safest, highest quality environment for those you serve. To learn more about how your organization can earn this respected "Gold Seal of Approval™," drop by booth #235, visit www.goldsealofapproval.org or call (630) 792-5866.

### Tower Systems, Inc.

17461 Irvine Blvd, Suite Y  
Tustin, CA 92780

Ph/Fax: 714-731-0491; 714-731-8637

jnielsen@towersys.com • www.methadoneclinics.com

If you're tired of hearing unfulfilled promises or relying on software that has yet to be delivered, it's time to open your eyes and take a good look at Tower Systems. With a host of CARE, JCAHO & COA accreditation tools, as well as HIPAA compliant 837 & 835 billing, it's time to expect more from your methadone management software provider.

### Treatment Software Solutions

P.O. Box 4429

Rockville, MD 20849

Sales Ph/Fax: 301-996-2181; 301-560-4988

stiles@clinicweb.net • www.clinicweb.net

ClinicWeb by Treatment Software Solutions is a comprehensive web-based clinical management solution for opioid treatment programs. Easy to use and affordable, ClinicWeb uses state of the art Microsoft technology to enhance the quality of care, facilitate regulatory compliance, and significantly reduce costs and paperwork.

### Booth #324

### VistaPharm

2224 Cahaba Valley Drive, Suite B3  
Birmingham, AL 35242

Ph/Fax: 205-981-1387; 205-980-4849

info@vistapharm.com • www.vistapharm.com

VistaPharm manufactures and distributes quality methadone products. We offer oral concentrate, dispersible tablets, tablets, and powder methadone. Our personalized services set us apart in our industry. We are accessible to address your needs in an expedient manner. Stop by our booth to meet the VistaPharm team.

### Booth #224

### Booth #220

### White Deer Run/Cove Forge/Bowling Green

204 East Calder Way, Suite 306  
State College, PA 16801

Ph/Fax: 814-861-6198; 814-861-6199

kkoptchak@crchealth.com • www.whitedeerrun.com

White Deer Run/Cove Forge Behavioral Health System/Bowling Green Brandywine is one of the leading systems in the nation for the treatment of drug and alcohol addiction. Each of our facilities provides a relaxed atmosphere that lends itself to personal reflection and healing for adults and adolescents alike.

### Booth #124

### Booth #229

### Willow Laboratories

280 Union Street Lynn, MA 01901

Ph/Fax: 781-268-2400; 781-268-2411

info@willowlabs.com • www.willowlabs.com

Willow Laboratories offers comprehensive laboratory based drug testing services including GC/MS and LC/MS/MS confirmations. In addition to our urine drug screening, we provide hair and saliva testing. Willow maintains a staff of pharmacologists, toxicologists, physicians, and certified medical technologists. Clients can access results online through www.willowlabs.com or directly with EMR.

### Booth #327

### Booth #214

### Wolters Kluwer Health/Lippincott

Williams & Wilkins

530 Walnut Street  
Philadelphia, PA 19106

Ph/Fax: 800-638-3030 (US, Canada) or 301-223-2300; 301-223-2400

customerservice@LWW.com • www.LWW.com


Lippincott Williams & Wilkins, a unit of Wolters Kluwer Health, is a leading international publisher of medical books, journals, and electronic media. Stop by our booth to purchase the latest clinical texts, pick up sample copies of our journals including the Journal of Addiction Medicine, and learn about our meeting specials.

### Browse Table

### Booth #235

### Booth #310

### Booth #226



## SPECIAL THANKS

*The American Association for the Treatment of Opioid Dependence, Inc.  
and the 2009 Conference Planning Committee  
acknowledge and give special thanks to:*

COMPA – New York State's Opioid Treatment Coalition

National Institutes of Health (NIH) – National Institute on Drug Abuse (NIDA)

New York State Office of Alcoholism and Substance Abuse Services (OASAS)

Substance Abuse and Mental Health Services Administration (SAMHSA), Center  
for Substance Abuse Treatment (CSAT)

### PLATINUM LEVEL SPONSOR

Covidien-Mallinckrodt

### GOLD LEVEL SPONSORS

Bendiner & Schlesinger, Inc.  
VistaPharm, Inc.

### SILVER LEVEL SPONSORS

Addiction Treatment Providers Insurance Program  
Colonial Management, LP  
David Szerlip & Associates, Inc.  
GlaxoSmithKline  
Netsmart Technologies  
OraSure Technologies, Inc.  
Reckitt Benckiser Pharmaceuticals, Inc.  
Roxane Laboratories, Inc.  
Smart Software Solutions

### BRONZE LEVEL SPONSORS

O. Berk Co. of New England Kols Containers, Inc.  
Tower Systems, Inc.



# new york city



American Association for the Treatment of Opioid Dependence, Inc.

*Plan to  
join us again!*

*October 23 - 27, 2010  
in Chicago*

## 2009 Continuing Medical Education – 31.75

### ASAM

“This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society of Addiction Medicine (ASAM) and American Association for the Treatment of Opioid Dependence (AATOD).

The American Society of Addiction Medicine designates this educational activity for a maximum of 31.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## 2009 Continuing Education Hours - 33.25

**NAADAC** – “AATOD is an approved provider through NAADAC, the Association for Addiction Professionals, Provider #000218. This program meets the criteria for up to 33.25 hours of continuing education.”



**NY OASAS** – The New York State Office of Alcoholism and Substance Abuse Services’ (OASAS) recognizes the approval by NAADAC and, as such, all relevant/training will be acceptable for CASAC, CPP and/or CPS initial credentialing and/or renewal clock hours.

**NBCC** – “This program has been approved by the National Board for Certified Counselors for up to 33.25 hours, Approval Number SP-1631.”

**ASWB** – AATOD, provider # 1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) [www.aswb.org](http://www.aswb.org), through the Approved Continuing Education (ACE) program. AATOD maintains responsibility for the program approved until 2010. Social workers will receive up to 33.25 continuing education clock hours.



AATOD has applied to the following organization for continuing education approval:

New York State Nurses’ Association (NYSNA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.